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Abstract 
Follicular lymphoma (FL) is classically described as an incurable disease characterised by 
a distinctive clinical course, with repeated relapses and remissions. A progressive 
shortening of the duration of each remission and an increased relapse rate after each 
response is typically described. Major recent developments in the management of 
patients with FL have been the introduction of haematopoietic stem cell transplant 
(HSCT) and of rituximab treatment, resulting in a significant improvement in the overall 
survival of patients diagnosed with FL in the recent era. Another major advance in the 
21st century is the introduction of 18-fluoro-deoxyglucose positron emission 
tomography (FDG-PET) for the staging of patients with lymphoma, which has proven to 
be more accurate than standard computer tomography. A new prognostic score, the 
Follicular Lymphoma International Prognostic Index 2 (FLIPI2) has been designed in the 
setting of these innovations.  
 The aim of this thesis is to examine how the introduction of such advances has 
impacted on the management and on the clinical course of patients with FL. It will 
specifically address the impact that FDG-PET has on the staging, management and 
prognosis of FL and it will compare the recently designed FLIPI2 in newly diagnosed FL 
patients with the pre-rituximab prognostic score (FLIPI). As mentioned, the introduction 
of rituximab and HSCT has contributed to the significant improvement in the outcome 
of patients with FL. This thesis will demonstrate how these developments have changed 
not only the outcome but also the clinical course of patients with FL and will assess the 
impact that prior treatment with rituximab has on the outcome of patients undergoing 
a HSCT.
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1.1 Historical perspective 
Lymphomas were not recognised as a separate disease entity until 1862 when the 
term ‘pseudo leukaemia’ was utilised to differentiate these cases from leukaemia (1). 
Follicular lymphoma (FL), as a subtype, was first recognised as Brill-Symmers disease, 
named after the two authors that first described it (2-3). Both authors described the 
disease as a benign chronic disorder characterised by generalised lymphadenopathy, 
spleen involvement and clinical response to radiotherapy. Gall et al in 1941 described 
the clinical course and pathological features of FL, disputing the benign nature of FL, 
reporting its ability to transform to a more aggressive disease in some patients (4-5).  
 
1.2 Epidemiology and pathology of FL 
Non Hodgkin lymphomas (NHL) account for 2% of malignancies in the UK. FL is the 
second commonest subtype of NHL with an annual incidence in the UK of 3-5/100,00, 
which increases with age (6). The median age at diagnosis is situated in the 6th decade 
of life. 
FL is included amongst the so-called ‘low-grade’ NHL and originates from follicle centre 
B-cells. FL cells express surface immunoglobulin and are characteristically CD5-, CD10+, 
CD19 +, CD20+, CD22+ and CD79a+. Genetically it is characterised by the presence of 
the chromosomal translocation t(14;18) in 85% of cases, resulting in the over-
expression of BCL2, an anti-apoptotic protein (7). According to the latest WHO 
classification FL is graded by counting the absolute number of centroblasts in ten 
neoplastic follicles per 40x high power field (HPF) (table 1). Grade 1 and 2 are 
recommended to be reported together as low grade. Grade 3b is considered to be 
more aggressive and is considered to be equivalent to diffuse large B-cell lymphoma 
(DLBCL) and thus it is treated as DLBCL (8). 
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Table 1: Follicular lymphoma grading (WHO 2008) 
 
 
 
 
 
 
 
1.3 Natural history and clinical course of FL 
1.3.1 Natural history, clinical course and presentation of FL 
Patients diagnosed with FL are usually asymptomatic, in spite of the fact that the 
majority present in an advanced stage at diagnosis, with generalised lymph node (LN) 
involvement. Bone marrow (BM) is also frequently involved at presentation in up to 
60% of patients. Less common extra-nodal sites include the gastrointestinal tract, skin, 
breast and testis (8). Symptoms can be related to the bulk or the site of the disease (if 
compressing vital structures), in addition to B-symptoms (fever, night sweats or 
unexplained loss of weight), but the performance status is normal in more than 90% of 
patients (1). 
FL remains incurable and as a result reoccurrence after treatment is the norm in most 
patients. There is no difference in the overall survival (OS) of patients initially managed 
expectantly and those patients treated at diagnosis. Therefore, patients can be 
managed expectantly at diagnosis if asymptomatic; however, most patients will 
eventually require treatment: only a small proportion of patients (10-19%) will never 
require treatment (9) . FL is characterised by its responsiveness to treatment, so the 
majority of patients will respond to first-line therapy. However, it is also characterised 
Grade  Definition 
Grade 1-2 (low grade) 0- 15 centroblasts per HPF 
Grade 1 0-5  centroblasts per HPF 
Grade 2 6-15 centroblasts per HPF 
Grade 3 >15 centroblasts per HPF 
Grade 3a Centrocytes present 
Grade 3b Solid sheets of centroblasts 
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by a typical pattern of relapses after each remission. With each relapse the likelihood 
of response to treatment and the duration of the remission decreases, as the disease 
becomes more resistant to treatment (10). 
 
1.3.2 Outcome of patients with FL over time 
Improvement in the OS of FL patients treated by combination chemotherapy regimens 
in comparison to single agent chemotherapy remained elusive for years, irrespective of 
the year of diagnosis, despite the achievement of better response rates and longer 
disease-free survival (DFS) (11) (figure 1). An improvement in the OS of patients with 
FL depending on the year of diagnosis was demonstrated for the first time by the 
analysis of the SEER data, showing an improvement in the median OS of FL patients 
diagnosed in the  1993 - 1989 era (93 months) compared with those diagnosed in the 
1983 - 1989 era (84 months) (12). Subsequent studies by the SWOG and M.D. 
Anderson Cancer Center compared the progression-free survival (PFS) and the OS of 
patients treated on their trials over 30 years (13-14). Both studies showed an 
improvement of OS by around 30% for patients treated in the  1990 era compared to 
patients treated in the 1970 era. This improvement in OS was attributed to the success 
of improved sequential treatment, better supportive care and, importantly, the 
inclusion of monoclonal antibody (MoAb) treatment. Thus, the current expected 
median OS of patients in the rituximab era is between 10 and 13 years.
 
Chapter One 
18 
Figure 1: OS remained unchanged over three decades 
 
 
 
1.4 Staging and the role of FDG-PET in patients with FL 
1.4.1 The importance of staging 
Staging is the process of identifying the extent of a disease at presentation. It provides 
the baseline assessment against which post treatment investigations should be 
compared with to assess response to therapy (1). The stage at diagnosis in patients with 
FL influences their management and is one of the most important prognostic factors. 
Furthermore, accurate staging enables comparisons of different populations treated in 
different centres, and allows comparisons amongst series and different clinical trials. 
Although the Ann Arbor staging system was initially designed specifically for Hodgkin 
lymphoma (HL) (15-17) it is utilised in the staging of all subtypes of lymphoma including 
FL. The classification was modified at the Cotswold meeting to include the recognition 
of bulky disease (≥ 10cm denoted by X) and to recommend the inclusion of 
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computerised tomography (CT) to evaluate intrathoracic and infradiaphragmatic LN 
(18). Notably, it has not undergone any changes since then. 
 
1.4.2 Imaging investigations and bone marrow biopsy 
The investigations utilised to determine the stage of a patient diagnosed with FL have 
changed over the decades as imaging technology has advanced. Before the advent of CT 
and its introduction into medical practice, several other procedures were employed, 
including frontal and lateral chest x-rays, lymphangiography, staging laparotomy and 
splenectomy, skeletal surveys and isotope liver and spleen scanning (19). Since its 
introduction into clinical practice, the CT has become the dominant imaging 
investigation in the staging of patients with lymphoma. It is a non-invasive, fast 
investigation when compared to lymphangiography and laparotomy. In addition it gives 
an overall view of the extent of disease thereby eliminating the need for multiple 
investigations (19). Furthermore, it is an easily reproducible investigation that can be 
utilised in the assessment of response to treatment. The major limitation of CT results 
from its dependence on size criteria. Consequently the presence of disease in normal 
sized LNs is difficult to identify, as is the presence of diffuse involvement in normal sized 
liver/spleen and BM disease. One of the advantages of lymphangiography in this regard 
was its ability to identify presence of disease in normal sized LN (19). 
Bone marrow aspirate and trephine (BMB) is the current gold standard for the 
assessment of BM involvement and is an essential part of staging in FL. The BM is 
involved in 40-60 % of patients presenting with FL (20). The presence of disease in the 
BM leads to a change in the stage, prognosis and frequently the management of 
patients with FL. However, BMB is an unpleasant procedure that can potentially miss 
disease not present in the biopsy area, or if the biopsy is inadequate in quality. 
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Performing a bilateral BMB can increase the sensitivity of the procedure by 10-22%; 
nevertheless, given its morbidity, most centres, including St Bartholomew’s Hospital, 
perform only unilateral BMB. 
 
1.4.3 18-fluoro-deoxyglucose positron-emission tomography (FDG-PET) 
Positron-emission tomography (PET) is a nuclear medicine functional imaging modality. 
It utilises a biological compound labelled with a positron-emitting radionuclide to 
produce an image which reflects a specific metabolic activity in the body. The PET 
detectors surrounding the patient are designed to detect the annihilation photons that 
are emitted simultaneously in opposite directions as a result of the interaction of 
ejected positrons from the radionuclide with electrons in the surrounding tissue (figure 
2). This allows PET to localise the points of origin of these photons and reconstruct an 
image with this information. The number of signals received by the PET detectors and 
the resulting intensity depicted in the 3D image reconstructed depends on the uptake, 
concentration and excretion of the positron emitting compound in the body (21).  
 
Figure 2: Interaction of released positron with electron, and detection of annihilation 
photons by PET (22) 
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1.4.4 Warburg effect and 18-fluoro-deoxyglucose 
Cancer cells have a higher rate of glucose uptake and metabolism than normal cells. 
This is due to the reliance of cancer cells on aerobic glycolysis even in the presence of 
oxygen. ATP production is faster via aerobic glycolysis but requires more glucose than 
oxidative phosphorylation (the pathway utilised in normal cells in the presence of 
oxygen). This unique metabolic characteristic of cancer cells that differentiates them 
from normal cells was first reported by Otto Warburg and is known as the ‘Warburg 
effect’ (23).  
18-fluoro-deoxyglucose (FDG) is composed of deoxyglucose (a glucose analogue) 
attached to a radioactive molecule 18-fluorine. After administering FDG intravenously it 
is preferentially taken up via glucose transporters which are over expressed in cancer 
cells and it is phosphorylated to FDG-6-phosphate by hexokinase enzyme. FDG-6-
phosphate is not able to enter glycolysis and is trapped in the cells (figure 3). As it 
decays, positrons are emitted and the resulting photons will be detected by the PET 
scanner (24). The more FDG is taken up in a tissue the more photons originating from 
that area will be detected by the PET scanner. FDG was first utilised in humans in 1976, 
since then has become the dominant PET tracer in use clinically (25). 
Figure 3: Uptake of FDG via glucose transporters on the cell membrane  
 
  
 
 
Glucose transporters 
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1.4.5 Analysis of PET images: visual and quantitative interpretation 
FDG-PET can be interpreted either by visual analysis, semi-quantitative or quantitative 
analysis. The most widespread and popular method in the routine practice is visual 
analysis. Visual analysis relies on the difference in the uptake of a tracer between the 
uptake in a lesion and the background uptake, where the uptake is not explained by the 
normal distribution of the tracer (26-27). Visual analysis of PET is currently the 
dominant method for reporting PET in patients with either HL or NHL, as recommended 
by the International Harmonization Project (IHP) (27). Visual analysis is dependent on 
the reporting physician in assessing whether a lesion with enhanced uptake is 
pathological or not: this is acknowledged as the main flaw of visual analysis as it makes 
it relatively subjective. The reference background being used by the physician is also an 
important factor, as this can be the surrounding background of the lesion, the 
mediastinal blood pool (MBP) or the liver (28). A ‘positive’ scan is defined by the 
presence of one or more lesions with increased uptake relative to the chosen 
background that is unaccounted for by physiological uptake. A ‘negative’ scan is where 
no abnormal uptake is seen relative to the chosen background.  
One of the hallmarks of PET is that it enables the quantification of metabolic uptake in 
lesions, which is not possible with any other imaging modality. There are different 
quantitative methods: some are complex and require dynamic data acquisition and 
blood analysis for tracer levels (29) but this type of analysis is usually limited to the 
research of new PET tracers. Standardised uptake value (SUV) is the simplest and most 
commonly used quantitative method. It measures the intensity of the tracer uptake at a 
defined time in a specific region. It is dependent on the injected activity of the tracer, 
uptake time and patient’s size (30). There are several methods used to define a region 
of interest (ROI) depending on the PET software in use, but there is currently no 
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consensus on which method is the best to define a ROI. It is important to note that the 
SUV recorded will vary according to the method utilised. Therefore a consistent method 
should be used within a patient group or study to ensure an accurate use of SUV for 
treatment monitoring (31). 
 
1.4.6 FDG avidity of FL  
A specific subtype of lymphoma is considered to be FDG-avid if there is an increased 
FDG uptake detected in involved sites of disease identified by conventional imaging. 
FDG avidity [expressed as the percentage of patients with FDG-avid lymphoma in 
relation to the total number of patients (32-33)] varies amongst different subtypes of 
lymphoma with a tendency towards the more aggressive lymphomas being more avid 
than the indolent lymphomas. However, FL has proven to be highly FDG-avid in contrast 
to other indolent lymphomas. Several studies investigating the avidity of FL consistently 
found that 94-100% of cases of FL are FDG-avid (34-35). This percentage is comparable 
to the results reported for both DLBCL and HL (32-33). The intense avidity of DLBCL has 
been associated with the high proliferative rate of DLBCL cells (36). Overall, FL has a low 
proliferative rate, and several clinical studies found no significant correlation between 
the measured SUVmax and the histological grading of FL (35, 37-38). An alternative 
hypothesis to explain FDG avidity in FL despite the low proliferation rate is the role of 
the surrounding microenvironment as a correlation between SUVmax and CD8+, CD68+ 
and CD34+ positive cells has been reported. There is however a paucity of studies in this 
area (39). 
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1.4.7 Current international and national guidelines 
The IHP published recommendations regarding the timing and interpretation of post-
treatment FDG-PET for DLBCL and HL in 2007 (27). A pre-therapy FDG-PET although 
deemed not obligatory by the IHP, was encouraged as it could facilitate post therapy 
PET interpretation for the recognised FDG-avid lymphomas: DLBCL, HL and FL (27). The 
European Society of Medical Oncology (ESMO) has more recently recommended an 
additional PET to the conventional staging investigations (CT of the neck, thorax, 
abdomen and pelvis, and a BMB) in rare cases to confirm localised stage I/II disease 
(40). The National Comprehensive Cancer Network (NCCN) has indicated that PET may 
be useful in selected FL cases (41). The guidelines of the Royal College of Radiologists 
recommend a FDG-PET to confirm staging in patients with early stage FL undergoing 
radiotherapy (42). In summary, the current available guidelines suggest that there may 
be a clinical value to a pre-therapy PET in certain circumstances, but overall they are 
vague and some do not elaborate on what exactly are the selected or rare cases. This is 
due to an absence of large prospective trials examining the clinical usefulness of a pre-
therapy PET in FL, which is reflected by the British Society of Haematology guidelines 
that do not recommend a FDG-PET for staging of FL until more data via clinical trials 
becomes available (43). 
 
1.4.8 FDG-PET clinical studies in FL 
The sensitivity of FDG-PET in FL ranges from 91 to 97% and the specificity is up to 100% 
when compared to conventional imaging methods (table 2). An additional 40-54% more 
nodal lesions and up to 89% more extra-nodal lesions can be detected by FDG-PET in 
comparison to conventional imaging. The unique ability of FDG-PET to identify disease 
involved normal-sized LN, as well as extra-nodal (e.g. bone, spleen and muscle) 
 
Chapter One 
25 
involvement results in the increased accuracy of FDG-PET to detect areas of disease, 
which might lead to a change in the stage and subsequently in the management of 
patients in a variable proportion of cases. 
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Table 2: Clinical studies evaluating the role of FDG-PET in FL patients  
 
 
NR: not reported by authors
Author  
(year) 
Patient characteristics % of additional lesions detected by 
PET 
% Avidity Sensitivity Specificity Change  
in stage 
(%) 
Upstaged 
(%) 
Change in 
management 
(%) 
Jerusalem 
(2001) (34) 
42 patients (24 FL) 40% more nodal areas 
 
100% NR NR NR NR NR 
Worher 
 (2006) (38) 
62 newly diagnosed  FL NR NR 98% 94% NR NR NR 
Karam 
 (2006) (35) 
17 newly diagnosed FL  NR 94% 94% 100% NR 29% NR 
Bishu 
 (2007) (37) 
31 grade 1-2 FL (16 newly 
diagnosed, 15 relapsed) 
NR NR 95% 88% NR NR NR 
Wirth 
 (2008)(44) 
42  FL  grade 1-3a stage 
I/II  
41 additional sites in 19 patients 97% NR NR NR 40% 45% 
Janikova  
(2008) (45) 
82  grade 1-3a FL (62 
newly diagnosed, 20 
relapsed) 
50%: additional sites 
(nodal:63%; extra-nodal:68%) 
NR NR NR NR 22% 18% 
Scott 
(2009) (46) 
74 newly diagnosed ‘low-
grade’ NHL (55 FL) 
50%  NR NR NR 32% 28% 34% 
Le Dortz  
(2010) (47) 
45 newly diagnosed  
grade 1-3a FL (treated 
with R-CHOP)  
51% (nodal) 
89% (extra-nodal) 
100% NR NR 18% 11% NR 
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1.5 Prognostic indices used in patients with FL 
The most recent clinical prognostic index specifically designed for FL is the Follicular 
Lymphoma International Prognostic Index 2 (FLIPI2) published in 2009 (48). This was 
preceded by the Follicular Lymphoma International Prognostic Index (FLIPI) which had been 
published in 2004 (49). Previous to the FLIPI the International Prognostic Index (IPI) was used 
for ‘indolent’ lymphomas including FL, although it was initially designed for aggressive 
lymphoma. The IPI was developed in 1993 for the prediction of OS and relapse-free survival 
(RFS) in patients with aggressive lymphoma (50). It is based on the presence of five 
prognostic factors (age >60 years, elevated serum LDH, number of extra-nodal sites >1, ECOG 
performance status (PS) >2 and Ann Arbor stage III/IV). The IPI was found to be also 
applicable in patients with ‘indolent’ lymphoma including FL (51). However, the main flaw of 
the IPI in FL is that it segregates very few patients to the high-risk group (<15%) and some 
prognostic factors such as the PS are not as useful in FL, as most patients have a good PS at 
diagnosis. A more specific prognostic scoring system for FL was needed and this led to the 
development of the FLIPI (52). 
 
1.5.1 Follicular Lymphoma International Prognostic Index (FLIPI) 
The FLIPI was the result of a multicentre retrospective analysis of prognostic factors in 4167 
newly diagnosed FL patients between 1985 and 1992 (in the pre-rituximab era) (49). OS was 
the end-point for the statistical analysis, whereas PFS was not analysed. Five prognostic 
factors were recognised: age >60 years, Ann Arbor stage III/IV, LDH >ULN, haemoglobin level 
<12g/dL and number of involved LN regions >4. The FLIPI segregated patients into three 
different risk groups: low-risk, intermediate-risk and high-risk groups, that are very well 
balanced in terms of the proportion of patients included in each group (table 3). Although 
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designed in patients who did not receive rituximab, the FLIPI has also been shown to be 
predictive of OS in the rituximab era (53). 
Table 3: Risk groups, 5-year and 10-year OS according to FLIPI  
 
Risk Group Number of factors Patients (%) 5-year OS 10-year OS 
Low-risk 0-1 36% 91% 71% 
Intermediate-risk 2 37% 78% 51% 
High-risk 3-5 27% 52% 35% 
 
1.5.2 Follicular Lymphoma International Prognostic Index 2 (FLIPI2) 
A prospective multicentre study was conducted between January 2003 and May 2005 and 
included 1093 patients with FL in an attempt to prospectively produce a new prognostic 
index in the era of rituximab. Patients managed expectantly were excluded from this model, 
as PFS was the chosen statistical end-point for the FLIPI2 trial and its definition differs 
between patients treated at diagnosis and those managed expectantly. The FLIPI2 includes 
five prognostic factors: age >60 years, BM involvement, diameter of the largest LN >6cm, 
raised beta-2-microglobulin (B2M) and haemoglobin <12g/dL. The presence of these factors 
divides patients into 3 risk groups: low-risk (0 factors), intermediate-risk (1-2 factors), and 
high-risk (3-5 factors). More than half the patients according to the FLIPI2 fall into the 
intermediate-risk group (table 4).  
Table 4: Risk groups and 5-year PFS according to FLIPI2  
 
Risk Group Number of factors Patients (%) 5-year PFS 
Low-risk 0 20% 79% 
Intermediate-risk 1-2 53% 51% 
High-risk 3-5 27% 19% 
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1.6 Management of patients with FL 
1.6.1 Management of patients with limited stage  
Most FL patients present in advanced stage, however 10- 20% of patients will present with 
limited stage at diagnosis (54). The recommended treatment for these patients adopted by 
international guidelines is involved field radiotherapy (IFRT) (40-41). This is based on the 
results of several small retrospective studies, which have reported the long-term outcome of 
limited stage patients treated with radiotherapy, with a 10-year DFS ranging from 41 to 49% 
and a 10-year OS of 62-79% (table 5) (55-58). Relapse of disease usually occurs outside the 
irradiated area, and the risk of late relapse (after 10 years) is very low in these patients (58). 
The potential ‘curative’ effect of local RT in patients with localised disease has been the basis 
for the generalised recommendation of RT as the ‘standard’ in localised stage FL. However an 
initial watch and wait policy was also shown to be an acceptable option in these patients, 
especially in patients with stage II disease with involvement of areas difficult to irradiate (59). 
There has been a paucity of prospective randomized trials in limited stage FL. A randomised 
prospective trial comparing IFRT versus IFRT and chlorambucil treatment for a total of 8 
months was performed and found no difference in DFS or OS between both groups (60). 
 
Table 5: Studies on limited stage FL 
 
Centre Treatment DFS at 10 years OS at 10 years 
Stanford (57) 35-50 Gy 44% 64% 
BNLI (55) 35 Gy  49% 64% 
Princess Margaret (58) 20-35 Gy 41% 62% 
MD Anderson (61) 30-40 Gy +COP-
Bleo/CHOP-Bleo 
Time to treatment 
failure:  72% at 10yrs 
80% 
Stanford (59) Watchful waiting - 85% 
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1.6.2 Management of patients with advanced stage  
Expectant management is recommended as the standard approach for asymptomatic 
patients lacking any criteria for treatment (40, 42). In contrast, there is currently no 
consensus on the standard chemotherapy regimen for symptomatic newly diagnosed 
patients. Treatment for advanced stage symptomatic FL is variable, and the options range 
from single agent immunotherapy (rituximab), combination treatment (R-CHOP, R-CVP, R-
FCM, R-MCP, ) and, in patients with recurrent disease, stem cell transplantation.  
 
1.6.3 Expectant management 
In 1979 Portlock et al demonstrated retrospectively that the OS in 44 asymptomatic patients 
diagnosed with  advanced stage low grade lymphoma , managed expectantly at diagnosis 
was not significantly different to the OS of 112  similar patients treated at diagnosis at 
Stanford University (62). The natural history of 83 asymptomatic patients with advanced 
stage untreated low grade lymphoma was further described by Horning et al from the same 
institution. The median time to treatment in this group of patients was 3 years, while 
spontaneous remission was seen in 23% of patients (63). 
Subsequently, there have been three randomised trials in the pre-rituximab era comparing a 
watchful waiting approach (WW) in asymptomatic advanced stage FL to immediate 
treatment. The BNLI trial compared chlorambucil with expectant management (9), while  the 
GELF-86 trial compared WW versus prednimustine versus interferon (64), and the National 
Cancer Institute trial compared WW versus ProMACE-MOPP (65). None of these studies 
found a difference in the OS of patients treated at diagnosis and those managed expectantly. 
The median time to treatment in the expectantly managed group ranged between 23 and 36 
months, and the median time to second progression and response to treatment was not 
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affected by deferral of treatment. In the BNLI study 19% of the patients did not require any 
treatment after 10 years of follow-up. 
In the rituximab era, the WW approach has been re-challenged with rituximab treatment in 
asymptomatic newly diagnosed FL patients. A prospective randomised trial (only published in 
abstract form) compared WW with rituximab weekly for 4 weeks or rituximab weekly for 4 
weeks followed by rituximab maintenance. Treatment with rituximab at diagnosis appears to 
delay further therapy as the median time to treatment was 33 months in the WW arm, while 
it was not reached at 4 years in the rituximab arms. However the follow-up was too short to 
detect any differences in OS (66).  
 1.6.4 Treatment criteria 
The identification of the ‘asymptomatic’ patients with FL who require treatment at diagnosis 
and the selection of signs/symptoms that warrant starting treatment are not well 
established. The currently available treatment criteria mostly used are the Groupe d’Etude 
des Lymphomes Folliculaires (GELF) (table 6)(67) and the British National Lymphoma 
Investigation (BNLI) (table 7) (9). Both were retrospectively described by expert opinion and 
are utilised in trials to define the characteristics of the patients that mandate initiating 
treatment. As a result , the GELF criteria in particular notably change between  different 
studies (64, 67-68). Most clinicians use probably a combination of  GELF and BNLI treatment 
criteria in clinic when deciding on when to start treatment. 
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Table 6: GELF criteria 
 
Bulky disease: nodal/extra-nodal ≥7cm 
3 involved nodal areas, each with a LN ≥3cm 
Spleen ≥20cm 
Pleural effusion/ ascites  
ECOG PS ≥2 
B-symptoms 
Elevated LDH/ B2M 
 
 
Table 7: BNLI criteria 
  
Rapidly progressive disease 
Life threatening organ involvement 
Bone lesions 
B symptoms/ pruritus 
Cytopenias due to BM involvement (Hb <10g/dL, 
WBC <1.0X109/mL, PLT <100 x 109/mL) 
 
1.6.5 Immuno-chemotherapy  
Several trials have demonstrated that the addition of rituximab to chemotherapy improves 
response rates, PFS and OS. A prospective trial comparing R-CHOP versus CHOP in newly 
diagnosed FL patients showed a better OS at 2 years for the R-CHOP group (95% versus 
90%).This study involved a second randomisation of responding patients (achieved CR or PR) 
,age <60 years to HDT/ASCT  or  interferon α maintenance. No difference in outcome was 
found between patients that had received  initial treatment with RCHOP or CHOP when 
randomised to HDT/ASCT. Whilst, patients that had received RCHOP and were randomised to 
interferon α maintenance were found to have a significantly longer duration of response 
than patients that had received  CHOP(69). Marcus et al  also reported  an improved OS  in  
newly diagnosed FL patients treated with R-CVP versus CVP, with a 4-year OS of 83% and 
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77%, respectively (70). Furthermore, the superior OS, response rates and improved disease 
control in patients receiving rituximab as part of their treatment regimen was confirmed by a 
meta-analysis of 1,480 FL patients from 7 prospectively randomised trials comparing R-
chemotherapy versus chemotherapy (5 trials in newly diagnosed and 2 trials in relapsed 
patients). In consequence, although there is no agreement on the type of chemotherapy to 
be used, there is general agreement that rituximab should be part of the treatment regimen 
offered to FL patients (71). 
 
1.6.6 Maintenance therapy with rituximab 
In an effort to improve survival in FL patients, maintenance with rituximab and radio- 
immunotherapy has been explored in several studies in both newly diagnosed and relapsed 
patients (67, 72-76). The EORTC intergroup study demonstrated an improved PFS in 
relapsed/resistant FL patients randomised after R-CHOP or CHOP to rituximab maintenance 
(median PFS: 3.7 years) versus observation (median PFS: 1.3 years). The PRIMA trial showed 
an improved PFS in newly diagnosed patients treated with immuno-chemotherapy who 
received maintenance with rituximab (PFS at 3 years: 75% and 58% for patients treated with 
maintenance rituximab and those managed expectantly, respectively) (76). Vidal et al 
demonstrated in a meta-analysis that all groups of patients benefited from an improvement 
in PFS from maintenance rituximab in comparison with patients that did not receive 
maintenance, regardless of whether they were previously untreated or had relapsed disease, 
and whether they had received rituximab or not as part of the induction regimen. In addition, 
patients with relapsed/refractory disease had an improved OS with rituximab maintenance in 
comparison with those who did not receive maintenance, whereas it was not possible to 
demonstrate a benefit in OS in untreated patients (77-78). A recent study presented only in 
abstract version, however, suggests that there is no difference in time-to-treatment failure 
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between patients receiving rituximab maintenance and those patients re-treated with 
rituximab at progression (79). 
 
1.6.7 High-dose therapy with autologous stem cell rescue (HDT/ASCR) 
In the pre-rituximab era, 3 prospective randomised trials explored the benefit of HDT/ASCR 
versus conventional chemotherapy in previously untreated FL patients. Both the GLSG and 
the GOELAMS trial found an improved PFS and EFS, respectively, for patients treated with 
HDT/ASCT, however in none of the trials an improved OS could be demonstrated (80-83). In 
contrast, the trial conducted by the GELA did not find any difference in EFS or OS between 
both groups of patients (HDT/ASCR and patients treated with CHVP + interferon) after a 
median follow-up of 7.5 years (83). In the rituximab era there is only one trial (conducted by 
the GITMO group) that randomised patients to R-CHOP treatment versus R-HDT/ASCR as 
first-line treatment. This trial demonstrated an improved PFS in the R-HDT/ASCR arm, but 
there was no difference in OS. The authors concluded that R-HDT/ASCR might represent an 
overtreatment for a significant proportion of newly diagnosed patients, and perhaps should 
be retained for patients with relapse or progression after R-CHOP (84). A systemic review and 
meta-analysis of HDT/ASCR versus conventional chemotherapy in the initial management of 
FL patients concluded that HDT/ASCR does not improve OS (85). 
Several retrospective studies reported a PFS of 28%-48% and an OS of 48%-54% at 10 years in 
relapsed patients treated with HDT/ASCR in the pre-rituximab era (86-90), but there is only 
one randomised prospective trial (the CUP trial) that compared HDT/ASCR with conventional 
chemotherapy in patients with relapsed FL. This trial demonstrated a better PFS and OS for 
patients treated in the HDT/ASCR arm (91). In contrast, a limited number of studies have 
explored the benefit of HDT/ASCR in relapsed patients in the rituximab era (92). A recent 
retrospective analysis by the GELA group of patients included in two previous randomised 
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trials that had received the same induction regimen analysed the role of rituximab and of 
HDT/ASCR at relapse. Patients that had received rituximab as part of the salvage treatment 
had a better OS than patients who had not received rituximab. However, patients that 
underwent HDT/ASCR after salvage treatment containing rituximab had the best OS and EFS 
when compared to patients that had received salvage treatment containing rituximab or 
patients that just had HDT/ASCR alone (93-94). 
 
1.6.8 Type of conditioning regimen in HDT/ASCR  
The majority of the prospective randomised studies examining the role of HDT/ASCR in the 
management of FL have included total-body irradiation (TBI) as part of the conditioning 
regimen (80-81, 83). However there has been a recent shift towards chemotherapy-based 
conditioning regimens in patients with FL, mostly due to reports of an increase risk of  
secondary myelodysplastic syndromes/ acute myelogenous leukemia (sMDS/AML) and other 
secondary malignancies in patients treated with TBI (82, 95-96). However, several factors 
other than TBI have been implicated, such as age, inclusion of etoposide in the conditioning 
regimen, cytogenetic abnormalities prior to transplant, previous radiotherapy exposure, prior 
alkylating therapy, number of prior lines of treatment and increased interval from diagnosis 
to HDT/ASCR (97-101). A retrospective analysis by the EBMT with a very long follow-up 
reported a shorter 5-year OS in patients treated with TBI-containing regimens, in comparison 
with patients who did not receive TBI. This was related to the higher non-relapse mortality 
(NRM) and a significantly higher risk of sMDS/AML in the TBI-treated group (89). These 
retrospective analyses were all performed in the pre-rituximab era but there has been no 
randomised trial comparing different conditioning regimens to date. Therefore currently 
there is no consensus on the type of conditioning regimen to be used in HDT/ASCR. 
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1.6.9 Allogeneic transplant and reduced-intensity conditioning regimens 
Allogeneic transplant is a potentially curable treatment in patients with FL. A PFS of up to 
43%  and an OS of 51% at 5 years has been reported with myeloablative conditioning 
regimens (102). However, a high treatment-related mortality (TRM) of up to 40% has been 
reported with myeloablative transplants (103). This has lead to a shift to non-myeloablative 
conditioning regimens or reduced-intensity conditioning (RIC) regimens, which are more 
feasible in the older patient population diagnosed with FL (104). In 1997 only 10% of 
allogeneic transplants for patients diagnosed with FL were RIC, whereas this has increased to 
80% in 2002 (105). This is due to the lower TRM of 25-31% achieved by this type of 
conditioning regimens. However, the relapse rate may be higher in patients receiving a RIC 
than standard myeloablative transplants (105). In addition, a recent study has shown that the 
TRM in myeloablative transplants has reduced in recent years as supportive measures have 
improved. The timing of an allogenic transplant and the best conditioning regimen are highly 
controversial, as there are no prospective trials comparing myeloablative and RIC 
conditioning or allogeneic transplant and HDT/ASCR (106). 
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2.1 Introduction 
Prognostic factors should be reproducible, easy to measure and predictive of outcome. Two 
prognostic indices have been developed specifically for patients with FL: the Follicular 
Lymphoma International Prognostic Index (FLIPI) and the FLIPI2. The FLIPI, described in 2004, 
was retrospectively designed in patients  diagnosed  with FL in the pre-rituximab era (49). It 
has been found to be predictive of OS and PFS in newly diagnosed FL patients (49, 53, 70), as 
well as of survival from progression in patients at first relapse (107). On the other hand the 
FLIPI2, a more recent prognostic index, was described in 2009 based on data prospectively 
collected in the rituximab era. The FLIPI 2 was found to be predictive of PFS in newly 
diagnosed  FL patients (48). 
The aim of this study was to compare the efficacy of the FLIPI and FLIPI2 in discriminating 
patients with newly diagnosed FL and a distinct outcome in terms of OS and PFS. 
 
2.2 Patients and methods 
2.2.1 Patients’ characteristics 
From 1985 to 2007, 302 patients (160 female/142 male; median age: 55 range: 24-89) were 
newly diagnosed with grade 1-3a FL in our institution. The FLIPI could be retrospectively 
assigned in 220 patients and the FLIPI2 in 149 patients. The 122 patients in whom both the 
FLIPI and FLIPI2 indices were assessable and could be assigned to a specific risk-group 
according to each index constitute the study population (table 8).  
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Table 8: Characteristics of the 122 patients in whom a risk group could be assigned according 
to both FLIPI and FLIPI2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.2 Definitions of end-points 
OS was measured from the date of diagnosis to the date of last follow-up or death. PFS was 
measured from the time of diagnosis to first treatment in expectantly managed patients, and 
from the time of diagnosis to relapse or progression in patients treated at diagnosis. A 
further sub-analysis of the OS and PFS was made in the subgroup of patients treated at 
diagnosis (n= 75). PFS was analysed from the time of diagnosis to relapse or progression in 
this subgroup.  
 
Patients characteristics (n=122) Patients, n (%) Missing values 
Gender (female) 75 (61%) 0 
Age, median (range) 56 years (25-87) 0 
Age ≥60 years 52 (43%)  
Stage  0 
I 14 (12%)  
II 22 (18%)  
III 21 (17%)  
IV 65 (53%)  
Histological grade  18 
Grade 1 53 (51%)  
Grade 2 27 (26%)  
Grade 3 24 (23%)  
Haemoglobin <12g/dL 21 (17%) 0 
Lactate dehydrogenase >ULN 22 (18%) 0 
Beta-2-microglobulin >ULN 20 (30%) 54 
Number of nodal sites >4 42 (39%) 14 
Lymph node size ≥6cm 31 (27%) 8 
Bone marrow involvement 55 (46%) 2 
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2.2.3 Statistical analysis 
The analysis of OS and PFS was performed by the Kaplan-Meier method and comparisons 
were made using the log-rank test. All causes of death were included in the OS analysis. 
Patients’ characteristics were compared with a t-test for continuous variables and a chi-
square or Fisher test for categorical variables. All statistical analysis was carried out on 
STATA. 
 
2.3 Results 
2.3.1 Patients’ treatment and follow-up 
From the study population, 75 patients (61%) received treatment immediately after diagnosis 
(of which, 25 patients received rituximab containing regimens), whereas the remainder (47 
patients) were managed expectantly. After a median follow-up of 7 years (range: 1-23), a 
further 30 patients subsequently received treatment. 
 
2.3.2 OS and PFS of the study population 
The median OS of the study group was 13.5 years, and the 5- and 10-year OS were 74% 
(95%CI: 65 -81%) and 58% (95%CI: 46-67%), respectively. The median PFS for the study group 
was 3.4 years and the 5 and 10-year PFS were 39% (95%CI: 30-48) and 21% (95%CI: 13-31%), 
respectively. There were no significant differences in OS (p= 0.57) or PFS (p=0.85) between 
the 122 patients comprising the study population and those patients in whom a risk-group 
according to one of the prognostic scores could not be assigned (180 patients).  
 
2.3.3 Patients’ distribution according to the FLIPI and FLIPI2 scores 
The distribution of the patients according to the FLIPI was as follows: 53 patients (42%) were 
assigned to the low-risk category, 35 patients (29%) to the intermediate category, and 34 
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patients (28%) to the high-risk category; whilst according to the FLIPI2 score 15 patients 
(12%) were included in the low-risk category, 78 patients (66%) in the intermediate-risk 
category, and 29 (24%) patients in the high-risk category (table 9). 
 
Table 9: Distribution of patients, OS and PFS according to the FLIPI and FLIPI2  
 
 
2.3.4 PFS according to the FLIPI and FLIPI2 indices 
The 5-year PFS according to the FLIPI score was 48% (95%CI: 34-60%) for the low-risk 
category; 46% (95%CI: 27-62%) in the intermediate-risk group, and 20% (95%CI: 10-35) for 
patients included in the high-risk category (p=0.001; figure 4). The 5-year PFS according to 
the FLIPI2 was 52% (95%CI: 25-74%) in the low-risk category, 43% (95%CI: 32-53%) in the 
intermediate-risk category, and 22% (95%CI: 10-39%) for the high-risk group (p=0.059; figure 
5). Thus, the FLIPI score predicted PFS (p=0.001) but was not able to discriminate patients 
with low-risk from those with intermediate-risk (p=0.6). There was a trend for the FLIPI2 to 
predict PFS (p=0.059) but it did not segregate the low-risk group from the intermediate-risk 
group (p=0.3). 
 
 
 
 
 
 
 
 
FLIPI  FLIPI2 
Risk group (n 
risk factors) 
% of 
patients 
5-year 
OS 
5-year 
PFS 
Risk group (n 
risk factors) 
% of 
patients 
5-year 
OS 
5-year 
PFS 
Low (0-1) 42% 93% 48% Low (0) 12% 93% 52% 
Intermediate 
(2) 
29% 79% 46% 
Intermediate 
(1-2) 
66% 85% 43% 
High (3-5) 28% 38% 20% High (3-5) 24% 33% 22% 
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Figure 4: PFS according to FLIPI risk groups in the study population 
 
 
 
Figure 5: PFS according to FLIPI2 risk groups in the study population  
 
 
 
2.3.5 OS according to the FLIPI and FLIPI2 indices  
The 10-year OS according to the FLIPI score in the low-risk category was 77% (95%CI: 60-
88%), in the intermediate-risk group it was 63% (95%CI: 41-78%), whereas it was 21% (95%CI: 
10-40%) in the high-risk category, as shown in figure 6. The 10-year OS according to the 
FLIPI2 in the low-risk category was 78% (95%CI: 32-95%), 66% (95%CI: 52-77%) in the 
intermediate category, and 22% (95%CI: 53-46) in patients included in the high-risk group 
(figure 7). The FLIPI and the FLIPI2 indices predicted OS (p<0.001, both for the FLIPI and the 
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FLIPI2), but the FLIPI2 did not accurately separate patients with low-risk from those with 
intermediate-risk in terms of OS (p=0.3), whereas the FLIPI score adequately segregated the 
study population in three distinct risk categories in terms of the OS (P<0.001). 
 
Figure 6: OS according to FLIPI risk groups in the study population 
 
 
 
Figure 7: OS according to FLIPI2 risk groups in the study population 
 
 
 
2.3.6 Patients treated immediately after diagnosis  
A sub-analysis of the group of patients who received treatment straightaway after diagnosis 
(n=75), excluding patients that were initially managed expectantly, was performed. The 
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distribution of the patients according to the FLIPI score was: 32 patients (43%) in the low-risk 
category, 18 patients (24%) in the intermediate category, and 25 patients (33%) in the high-
risk category; the distribution according to the FLIPI2 was as follows: 11 patients (15%), low-
risk; 43 patients (57%), intermediate group; and 21 patients (28%), high-risk category. The 
FLIPI score predicted PFS (p=0.002; figure 8) but was not able to discriminate patients with 
low-risk from those with intermediate-risk (p=0.9). In contrast, the FLIPI2 did not predict PFS 
(p=0.25) in this group of patients (figure 9). 
 
Figure 8: PFS according to FLIPI risk groups in patients treated at diagnosis 
 
 
Figure 9: PFS according to FLIPI2 risk groups in patients treated at diagnosis 
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The FLIPI and the FLIPI2 indices predicted OS (p<0.001 both for the FLIPI and the FLIPI2; 
figures 10 and 11). 
 
Figure 10: OS according to FLIPI risk groups in patients treated at diagnosis 
 
 
 
 
Figure 11: OS according to FLIPI2 risk groups in patients treated at diagnosis 
 
 
 
2.4 Discussion 
A risk group according to the FLIPI score could be assigned to 220 patients of 302 patients 
that were assessed (73%), while 149 patients (49%) were assigned a risk-group according to 
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the FLIPI2 score. The limiting factor with regards to the FLIPI2 assignment in our population 
was the availability of the B2M results. Of note, the lack of availability of B2M from 
contributing centres prevented its inclusion in the FLIPI, although it was recognised as an 
important prognostic factor for patients with FL.  
In our study, the FLIPI successfully segregated patients into three risk groups, well-balanced 
in terms of the proportion of patients in each group and with a distinct OS in both the overall 
group (p<0.001) and in the group of patients treated at diagnosis (p<0.001). In contrast, 
according to the FLIPI2 the majority of patients fell into the intermediate-risk category (66%). 
These findings were consistent in the sub-analysis of the 75 patients treated at diagnosis: in 
this subgroup 57% of the patients were classified as intermediate-risk. Furthermore, also in 
the original description of the FLIPI2 reported by Federico et al, the majority of patients 
(53%) fell into the intermediate-risk category (48). 
Although the FLIPI2 could separate a high-risk population with a short 5-year OS of 33%, it 
did not separate the low-risk and the intermediate-risk groups (5-year OS, 93% and 85%, 
respectively, p=0.3). These findings mirror the results from a similar study that 
retrospectively assessed the prognostic relevance of FLIPI2 in terms of OS and time to 
treatment failure in 758 patients, where the FLIPI2 could not differentiate between low-risk 
and intermediate-risk groups according to OS (108).  
With regards to PFS, the FLIPI discriminated a high-risk population with a short 5-year PFS 
(20%), but it was poor at differentiating the low and intermediate-risk groups (5-year PFS of 
48% and 46%, respectively). On the other hand the FLIPI2 tended to separate a high-risk 
population with a shorter PFS (22%), but was unable also to separate the low-risk from the 
intermediate-risk group (5-year PFS: 52% versus 43%; p=0.3). Interestingly, in our study the 
FLIPI2 additionally identified a low-risk group of patients that had a plateau in the PFS curve, 
with a similar PFS at 5 and 10 years. However, there were a very small number of patients in 
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our study that had a low-risk FLIPI2 score so this suggestion of a plateau in patients with low-
risk FLIPI2 needs to be verified with a longer follow-up in a larger group of patients. While 
both indices are good at defining a high-risk population with a shorter PFS, both are poor at 
separating the low and the intermediate-risk groups. Of note, the high-risk group includes a 
relatively small proportion of patients, so most patients with a similar prognosis in terms of 
PFS are indistinctly grouped together by both indices.  
In addition to characteristics related to the patients or to the disease itself, PFS is influenced 
by a number of factors. A major determinant of PFS is the type of treatment the patients 
receive, as PFS is a measure of how well a patient does in response to that treatment, 
whereas OS is a cumulative measure of the effect of multiple treatments a patient receives 
(109). In our study, the patients received a variety of different treatments, including 
rituximab in one third of treated patients. Although the FLIPI2 was intended for patients 
treated in the new era of rituximab, only 62% of the patients actually received rituximab in 
the study by Federico et al (48) and the patients, as in our study, received different 
treatments regimens. In addition, PFS is dependent on the timing of progression. The 
definition of time of progression, in a disease such as FL in which patients can be managed 
expectantly at progression, may differ between institutions and is liable to bias, contrasting 
with OS measurement in which the date of death is known and not disputable (109). Due to 
the above reasons, the replication of a prognostic score with PFS as an end-point may be 
difficult between different studies and not practical when patients have not received a 
similar treatment.  
 
2.5 Conclusions  
In summary, in our study both indices are good at defining a high-risk population with a short 
OS and a short PFS, but do not accurately segregate the rest, resulting in a relatively large 
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group of patients with a similar prognosis. According to our results, the FLIPI2 does not 
appear to be superior to FLIPI for risk stratification. Finally, the PFS may not be an 
appropriate end-point for patients treated heterogeneously. 
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CHAPTER THREE 
 
The role of FDG-PET/CT in the staging and 
prognosis of patients with follicular 
lymphoma 
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3.1 Introduction 
Staging according to the Ann Arbor classification describes the extent of the disease and is a 
cornerstone in the management of patients with FL (8), as the prognosis and type of 
treatment offered to patients depends on the stage at presentation. Patients with localised 
disease (I-II) can be offered radiation therapy, which is considered curative is some cases, 
whereas asymptomatic patients with advanced stage (III-IV) can be managed expectantly 
until they become symptomatic requiring institution of treatment.  
Currently the FLIPI is the most commonly used prognostic index in FL. It is based on a score 
defined by the presence of five prognostic factors. This score allows classifying patients into 
three risk groups (49). Two of the prognostic markers included in the FLIPI are dependent on 
imaging: the stage and the number of involved nodal areas. 
The imaging method of choice in patients with FL recommended by several international 
guidelines is still a contrast enhanced CT (CeCT), as there is a lack of consensus on the 
additional role of 18 fluoro-deoxyglucose positron-emission tomography (FDG-PET) in the 
staging of FL (40-41). In addition, most studies to date have investigated the role of  staging 
FDG-PET or FDG-PET/CT using a visual interpretation (34-35), but there is a paucity of studies 
examining the value of additional semi-quantitative analysis (33). The aim of this study was 
to investigate the role of FDG-PET/CT in the staging of FL and its consequent impact on the 
prognostic score (FLIPI) and on the management of patients in comparison with staging by 
CeCT. An additional objective was to examine the usefulness of semi-quantitative 
measurement to identify BM involvement in patients with FL by FDG-PET/CT. 
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3.2 Patients and methods 
3.2.1 Patients’ characteristics 
Between January 2008 and July 2011, 41 patients (median age: 64 years, range: 30-87) 
diagnosed with FL (grade 1-3a) were included in this study. All patients had a FDG-PET/CT, a 
CeCT and a unilateral BM aspirate and trephine (BMB) as part of the staging investigations. 
Seventy-five percent of the patients had their staging FDG-PET/CT and CeCT on the same day 
(range: 0–75). Thirty patients had not been treated previously while 11 had received prior 
treatment and had their staging investigations at relapse. The last treatment for patients 
included at relapse was administered at least 3 months (range: 3-54 months) prior to the 
staging investigations. The main characteristics of the patients are shown in table 10.  
 
Table 10: Patients' characteristics 
 
 
 
 
 
 
 
 
 
 
 
3.2.2 FDG-PET/CT acquisition 
All the FDG-PET/CT images were acquired on a Phillips Gemini TF LSO 64 slice scanner at one 
site. Images utilised in the visual and semi-quantitative analysis were acquired in 3D and 
 Patients, n (%) 
Age, median (range) 64 years (30-87) 
Gender (female) 22 (51% ) 
LDH >ULN 8 (20%) 
Haemoglobin <12mg/dL 11 (26%) 
LN >6cm 5 (12%) 
Histological grade 
Grade 1 7 (16%) 
Grade 2 23 (55%) 
Grade 3a 8 (18%) 
Unknown 3 (7%) 
Management at diagnosis 
Immediate treatment 21 (51%) 
Expectant management  
 
 
 
 
20 (49%) 
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reconstructed using OSEM (ordered subset expectation maximization; 33 subsets, three 
iterations, no filters). All patients fasted for 6 hours and the median uptake time was 60 
minutes. Half body imaging was acquired in 10 or 11 bed positions from skull base to thighs. 
The low dose (LD) CT scan for attenuation correction and anatomical localization was 
performed at 120Kvp and 60mAs (table 11). Additional views of the head and neck were 
acquired at the end to minimize effects of patient movement. Diagnostic CTs were 
performed either on the PET/CT scanner with 120 kVp, 99mAs (maximum-dose modulation 
used) and a pitch of 0.83 or on a Siemens CT scanner using 120kVp and mAs modulation with 
"Caredose" (which optimally reduces dose), pitch at 1.5mm. 
 
Table 11: FDG-PET acquisition parameters 
 
 
 
 
 
3.2.3 Imaging analysis 
FDG-PET/CT images were interpreted both visually and by semi-quantitative assessment. 
Lymph node regions were defined as per the FLIPI. The number of involved nodal areas was 
recorded by both modalities, FDG-PET/CT and CeCT. A positive lesion was defined by visual 
analysis as an area of increased uptake, higher than the mediastinal blood pool (MBP), 
unrelated to physiological sites and consistent with a defined anatomical site on CT. Spleen 
and bone involvement were defined by an increased uptake higher than the liver. 
Semi-quantitative analysis involved measuring the maximum SUV (SUVmax) at all involved 
regions. The SUV was calculated according to the formula SUV = tissue activity (kBq/ml)/ 
activity injected (MBq/kg). The SUVmax was calculated using the single maximum pixel value 
FDG-PET/CT 
Uptake period: median (range) 60 min (53-78) 
Fasting glucose: median (range) 5.2 mmol (4.0-7.6) 
Injected activity: median (range) 349 MBq (249-399) 
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within a defined ROI and it was measured in all lesions. In addition, the SUVmax was 
measured in the bone regions usually involved by disease: the sternum, both iliac blades and 
the T12 vertebra (as a representation of the central skeleton). The average maximum SUV 
(SUVav) was calculated for these 4 sites and compared to the BMB result. The single highest 
SUVmax in the four sites as well as the ratios SUVav/MBP and SUVav/liver were also 
compared to the BMB result.  
 
3.2.4 Statistical analysis 
The BMB was considered the gold-standard to define BM involvement so patients were 
classified as having BM involvement or not according to it. A normal distribution for both 
populations (patients with and without BM involvement) was assumed. The two populations 
did not have equal variance, as shown by Levene’s test for equal variances; therefore a t-test 
for unequal variances (the Welch test) was performed, using SPSS. The t-tests were 
performed for the SUVav, the highest BM SUVmax, SUVav/MBP and SUVav/liver. Optimal 
SUVmax, SUVav, SUVav/MBP and SUVav/liver cut-offs were defined by Receiver Operating 
Characteristic (ROC) curves. 
 
3.3 Results 
3.3.1 Staging and management 
Thirty-seven patients (90%) had increased FDG uptake in a pathological site on FDG-PET/CT. 
The four patients that had no pathological uptake on FDG-PET/CT had no pathological lesions 
on CeCT or disease on BMB. FDG-PET/CT identified more involved nodal lesions (178) in 
comparison to CeCT (154). When taking into account the results of the BMB in combination 
with the CeCT, there was a change in stage in 29% of the patients, with 10% (4 patients) 
being up-staged by FDG-PET/CT (table 12). Two patients would be up-staged from stage I on 
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CeCT + BMB to stage III and IV as a result of the findings on the FDG-PET/CT, and another 2 
patients from stage II on CeCT + BMB to stage III and IV, respectively, after FDG-PET/CT. All 
four patients would have been up-staged to an advanced stage from localised stage, which 
would have led to a change in management based on FDG-PET/CT. The rest of the patients 
would have been down-staged by FDG-PET/CT, as 10 patients had BM involvement on BMB, 
not identified visually on FDG-PET/CT. 
 
Table 12: Staging according to imaging modalities 
 
Stage CeCT CeCT + BMB FDG-PET/CT 
0 3 (7%) 3 (7%) 3 (7%) 
I 6 (14%) 5 (12%) 3 (7%) 
II 5 (12%) 4 (9%) 3 (7%) 
III 21 (51%) 11 (26%) 20 (48%) 
IV 6 (14%) 18 (44%) 12 (29%) 
 
Ten patients had an increased tracer uptake in the spleen on FDG-PET/CT and thus were 
identified as having splenic involvement. Seven patients had a diffuse increase in uptake 
higher than the liver uptake, while 3 patients had focal lesions with increased uptake (2 with 
single lesions and 1 with multiple lesions). The mean SUVmax for involved spleens was 4.0 
(range: 3.1-6.9) while it was 2.2 (range: 1.1-3.0) for uninvolved spleens. Four patients had an 
enlarged spleen on CeCT, but did not have an increased uptake on FDG-PET/CT (although the 
enlargement of these spleens could also be demonstrated on the low-dose component of the 
CT) (table 13, figure 12). One patient had focal liver lesions on CeCT, identified by an 
increased uptake on FDG-PET/CT, while another patient had an enlarged liver on CeCT, but 
no increased uptake detected on FDG-PET/CT. 
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Table 13: Spleen involvement by FDG-PET/CT versus CeCT 
 
 FDG-PET+VE FDG-PET -VE 
CeCT +VE 4 4 
CeCT -VE 6 27 
  
Figure 12: Spleen and liver involvement seen on FDG-PET but not on CeCT 
 
        
 
3.3.2 Prognostic score: FLIPI 
The use of a FDG-PET/CT resulted in a change in the FLIPI score in 20% of the patients, with 2 
patients moving from the low-risk group to the intermediate-risk, while 10% of the patients 
moved from the intermediate-risk group to the high-risk. In this group of patients, staging by 
FDG-PET/CT would result in more than 50% of the patients being included in the high-risk 
category of the FLIPI (table 14).  
Table 14: FLIPI score according to FDG-PET/CT versus CeCT+ BMB 
 
 
 
 
 
 
 
FLIPI risk groups CeCT + BMB FDG-PET/CT 
Low-risk (0-1) 15 (37%) 12 (29%) 
Intermediate-risk (2) 7 (17%) 6 (15%) 
High-risk (3-5) 19 (46%) 23 (56%) 
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3.3.3 Bone marrow involvement 
BMB identified BM involvement in 16 patients (37%), of which 9 patients had ≤10% 
infiltration of the BM. On visual analysis of the FDG-PET/CT, 7 patients had BM involvement 
(focal lesions in 6, of which 4 patients had multifocal bone lesions). Two patients deemed to 
have possible bone involvement on visual analysis of the FDG-PET/CT had a negative BMB 
(table 15, figure 13). Visual analysis had thus a sensitivity and specificity of 31% and 92%, 
respectively.  
 
Table 15: Bone marrow involvement detected by FDG-PET/CT versus BMB  
 
 BMB +VE BMB -VE 
FDG-PET/CT +VE on visual analysis (n patients)  5 2 
FDG-PET/CT –VE on visual analysis (n patients) 11 23 
 
 
Figure 13: Bone involvement in scapulae detected by FDG-PET but not by CeCT 
 
 
  
 
All semi-quantitative measurements were significantly higher in patients with a positive BMB 
in comparison with those with a negative BMB (table 16). The sensitivity and the specificity 
for SUVmax ≥2.5 were 56% and 84%; those of SUVav ≥2 were 63% and 96%, and the 
sensitivity and specificity of SUVav/liver ≥0.75 were 81% and 80% respectively. The ratio 
SUVav/MBP ≥1 had the best sensitivity of 88% with a specificity of 80%. 
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Table 16: Accuracy of methods utilised in the assessment of BM involvement 
 
Methods for assessment of BM 
involvement 
BMB +VE BMB-VE p-value 
SUVmax 2.8 2.0 0.02 
SUVav 2.3 1.6 0.004 
SUVav/liver 1.0 0.6 <0.001 
SUVav/MBP 1.4 0.9 <0.001 
 
3.4 Discussion 
The addition of FDG-PET to CT has led to a powerful combination of both metabolic and 
structural imaging. Following the introduction of CT in the early 1980 era the criticism 
directed at CT was the complete reliance on the anatomical detection of enlargement of 
Lymph nodes and organs. Thus structurally normal LN and organs involved with disease were 
no longer detectable when relying only on CeCT.  The possible under-staging of patients as a 
result was recognised as an accepted flaw when compared to the morbidity of laparotomy 
and lymphangiography.  
It is now recognised that FL is an FDG-avid lymphoma. This is corroborated in our series, as  
90% of the patients had an FDG-avid disease (32). Several studies have now demonstrated 
that FDG-PET identifies additional areas of both nodal and extra-nodal disease in comparison 
to standard imaging modalities in patients with FL (34-35, 37, 45-47). Le Dotz and colleagues 
showed that this was as much as 51% for nodal disease and 89% for the detection of 
additional extra-nodal lesions (47). In our series FDG-PET/CT identified more involved LN 
regions than CeCT leading to a change in the stage in around one third of patients. 
Furthermore, FDG-PET has been found to have a sensitivity of 80-100% in the detection of 
splenic involvement, in comparison with the sensitivity of 33-94% of CT (depending on the 
size criteria used by the investigator) (110). In line with this, in our series 6 patients with 
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normal size spleen on CeCT were found to have increased uptake on FDG-PET/CT, compatible 
with splenic involvement. 
The critical issue is whether up-staging the patients using FDG-PET/CT would result in a 
change in the management of these patients. As the management of patients with stage III or 
IV does not differ, only patients with localised disease (I-II) up-staged to an advanced stage 
by FDG-PET/CT would have their management modified, as they would not be treated with 
local radiotherapy. In a study by Writh et al only early stage FL patients were included which 
led to a 45% change in the management of patients (44). In our retrospective analysis, 4 
patients were up-staged by FDG-PET/CT. Two of these patients had focal bone lesions on 
FDG-PET/CT not apparent on CeCT or BMB, while the other 2 patients had additional nodal 
regions involved both above and below the diaphragm, not seen on conventional imaging. If 
FDG-PET/CT had not been done, these patients would have been treated ineffectively with 
local radiotherapy. These data suggest that FDG-PET/CT staging provides more accurate 
information than conventional imaging whilst there is little difference in the amount of 
radiation a patient is exposed to if a low-dose CT protocol is used with PET. 
The FLIPI, the current prognostic index for FL, is not used to determine the management of FL 
patients, however it is utilised to predict prognosis, as well as in clinical trials to define and 
compare different patient populations. In the current study FDG-PET/CT identified 
significantly more LN regions than CeCT, which led to a change in the FLIPI score in 20% of 
patients, with most patients being up-graded to a higher risk category.  Whether the patients 
that appear to have a higher FLIPI score by FDG-PET/CT indeed have a worse prognosis, is 
difficult to ascertain with the current available data. Larger number of patients and longer 
follow-up would be necessary to answer this question. Nevertheless, a potential change in 
the FLIPI score by FDG-PET/CT should be taken into account when comparing different study 
populations.  
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BMB is an essential part of the staging of patients with FL, as 40-60% of them have BM 
involvement at presentation (8). However, given the patchy infiltration of BM in patients with 
FL, BMB -an unpleasant investigation- can miss disease not present in the biopsy area. 
Several studies evaluating the role of FDG-PET/CT in assessing BM involvement have relied 
on visual analysis, which has proved inadequate in FL. This is reflected in our experience as in 
our patient group the visual analysis of BM involvement had a high specificity but a sensitivity 
of only 31%.  FDG-PET is unique in its ability to provide quantitative assessment, in 
comparison to other anatomical imaging modalities such as CT and MRI. This additional 
characteristic is now gaining recognition in DLBCL, as SUVmax is being utilised to successfully 
assist visual interpretation of interim FDG-PET. In the present series, all the parameters that 
were assessed in the semi-quantitative analysis (SUVmax, SUVav, SUVav/MBP and 
SUVav/liver) were significantly different between patients with a positive and a negative 
BMB. Although we found that a cut-off of 2 for SUVav has a sensitivity of only 63% and a 
specificity of 97%, we found that a ratio of SUVav/MBP ≥1 increased the sensitivity to identify 
BM involvement to 88% while maintaining a high specificity of 80%. Absolute SUV 
measurements are affected by variations in blood sugar, duration of FDG uptake period and 
FDG injected activity. The use of ratios will minimize this error, as another measurement is 
utilised as a comparator to counter these effects. If these results are confirmed in further 
prospective studies, they may help to select patients who might benefit from having a BMB 
because of likely involvement, with the potential to consider avoiding BMB in the rest. 
 
3.5 Conclusions 
FDG-PET/CT identifies more involved LN and extra-nodal regions than conventional CeCT. 
This results in up-staging of patients which can in turn result in alternative management 
plans. In addition, the FLIPI score of patients staged by FDG-PET/CT differs from that in 
 
Chapter Three 
 60 
patients staged by CeCT. This needs to be taken into account when comparing the population 
of patients and the results from different centres utilizing a mixture of imaging techniques. 
Semi-quantitative measurement utilizing SUVmax has the potential to increase the specificity 
and sensitivity of FDG-PET/CT in identifying patients with involved BM. 
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CHAPTER FOUR 
 
Criteria for treatment and prognostic indices 
in patients with follicular lymphoma 
managed expectantly 
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4.1 Introduction 
Three major prospective randomised trials have demonstrated that asymptomatic patients 
with FL managed expectantly at diagnosis have a similar survival to that of patients treated 
immediately after diagnosis. The median time to treatment for the patients managed 
expectantly in these studies was around 3 years and 5-19% of them never required any 
treatment (9, 64-65). These studies constitute the basis to consider a watch and wait (WW) 
approach as the current standard for asymptomatic patients with advanced stage FL. 
However, expectant management in asymptomatic advanced FL patients has recently been 
challenged with the advent of rituximab, a very effective, relatively non-toxic treatment. 
Thus, Ardeshna et al recently reported a superior PFS in patients treated initially with 
rituximab in comparison to patients managed expectantly, although the follow-up was too 
short to show any significant differences in OS (66). 
Nevertheless, as there is not a curative treatment for advanced FL, expectant management 
remains the standard approach in asymptomatic patients. However, the ‘right time’ to start 
treatment is arbitrary, and differs between institutions. There are two main sets of criteria 
that are generally used to guide decisions on when to start treatment: the Groupe d’Etude 
des Lymphomes Folliculaires (GELF) and the British National Lymphoma Investigation (BNLI). 
However, both are the result of expert opinion and neither of these criteria is based on 
prospective clinical trials. 
On the other hand, patients managed expectantly have been excluded from the design of 
prognostic indices for newly diagnosed FL: only treated patients were retrospectively 
included in the design of the FLIPI (49), while patients managed expectantly were excluded 
from the prospective analysis of FLIPI2 (48, 50). 
Against this background, the objectives of this study were: 1) to assess the actual application 
of the GELA and BNLI criteria in the routine practice and their potential prognostic value, and 
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2) to analyse the predictive value of FLIPI and FLIPI2 to guide initiation of treatment in this 
population.  
 
4.2 Patients and methods 
4.2.1 Patients’ characteristics 
Three hundred and two patients [median age: 55 years, range (29-85)] newly diagnosed with 
FL presented to our institution between 1985 and 2007. One hundred and ninety-seven 
patients were treated at diagnosis, while 105 patients were followed-up expectantly and 
constitute the study population. Patients’ characteristics are shown in table 17. 
 
4.2.2 Definition of end-points 
Patients that had not received any treatment (chemotherapy or radiotherapy) within 3 
months of diagnosis were considered to be on expectant management. OS was measured 
from the date of diagnosis to death from any cause. Time-to-treatment (TT) was measured 
from the time of diagnosis to the time of initiation of  first treatment. 
 
4.2.3 Statistical analysis 
Survival analysis and duration of remission was performed by the Kaplan-Meier method and 
comparisons were made using the log-rank test. All causes of death were included in the OS 
analysis. Continuous variables between two different groups were tested by t-test. All 
statistical analysis was carried out on STATA. 
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Table 17: Characteristics at diagnosis of 105 patients managed expectantly  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3 Results 
4.3.1 Patients’ treatment and follow-up 
After a median follow-up of 90 months (range: 14-264), 33 patients (31%) have never 
required any treatment, whilst 72 patients have required treatment (31, single agent 
alkylating; 13, anthracycline-containing regimens; 24, a rituximab-containing regimen; and 4 
patients, other treatments). There were no significant differences in age, gender, histological 
grade, number of involved LN regions or FLIPI score between patients that never required 
 Patients, n (%) 
Gender (female) 52 (50%) 
Age ≥60 years 41 (39%) 
Stage   
I 9 (9%) 
 
II 19 (18%) 
III 23 (22%) 
IV 53 (51%) 
Unknown 1 
Histological grade    
Grade 1  52 (50%) 
Grade 2 32 (30%) 
Grade 3   
 
15 (13%) 
Unknown 6 (7%) 
Haemoglobin <12g/dL   20 (21%) 
Unknown  9 
Lactate dehydrogenase >ULN 3 (4%) 
Unknown  24 
Number of nodal sites >4 27 (35%) 
Unknown  27 
Beta-2-microglobulin >ULN 5 (20%) 
Unknown   80 
Bone marrow involvement 
 
45 (45%) 
Unknown   4 
Lymph node size ≥6cm  
 
 
 
10 (9%) 
Unknown 16 
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treatment and patients that eventually were treated. However, the group of patients that 
never required any treatment were less likely to have a LN mass ≥ 6cm (p=0.02). 
 
4.3.2 Prognostic indices 
The FLIPI and FLIPI2 score could be retrospectively assigned in 71 patients and 56 of the 105 
patients managed expectantly, respectively. The distribution of the patients in risk groups 
according to the FLIPI and FLIPI2 were not significantly different in patients managed 
expectantly in comparison to patients treated at diagnosis (p=0.89 and p=0.22, respectively) 
(table 18). 
 
Table 18: Distribution of patients according to FLIPI, FLIPI2 and treatment at diagnosis 
 
FLIPI FLIPI2 
Risk group W&W  Treated Risk group W&W Treated 
Low-risk (%) 32 (45%)  67 (45%) Low-risk (%) 4 (7%)  12 (13%) 
Intermediate-risk (%) 21 (30%) 39 (26%) Intermediate-risk (%) 43 (77%) 59 (63%) 
High-risk (%) 18 (25% 
) 
43 (29%) High-risk (%) 9 (16%) 22 (24%) 
 
4.3.3 Treatment criteria 
A total of 12 patients were found to have at least one BNLI criteria, while 20 patients had at 
least one GELF criteria (4 patients had more than one criterion) (table 19). Twenty-four of 
105 patients managed expectantly (23%) had at least one GELF or BNLI criteria for treatment. 
None of the patients evaluated had symptomatic compression of a vital organ, or life 
threatening organ involvement. 
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Table 19: GELF and BNLI criteria for treatment 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.4 Time-to-treatment 
The median TT for the 72 patients who eventually required treatment was 31 months (range: 
5-248). Both the FLIPI and the FLIPI2 predicted TT (p=0.02, p=0.04 respectively) and identified 
a high-risk population with a shorter TT. Patients with a high-risk FLIPI score and a high-risk 
FLIPI2 score were treated at a median of 2.6 years and 2.7 years, respectively, in comparison 
to a median of 5 years and 3.2 years for low-risk patients as per FLIPI and FLIPI2, respectively 
(figures 14 and 15). In contrast, there were no significant differences in TT between the low-
risk and intermediate-risk groups according to the FLIPI and FLIPI2. The median TT in the 
intermediate-risk group was 4.9 years and 3.8 years according to the FLIPI and FLIPI2, 
respectively. 
 
 
 
 
GELF/BNLI criteria Patients, 
n (%) 
GELF/BNLI criteria Patients, 
n (%) 
B-symptoms 6 (7%) Spleen ≥20 cm  1 (1%) 
Unknown 19 Unknown 11 
Lymph node mass ≥7cm 3 (3%) Pruritus 2 (2%) 
Unknown 11 Unknown 19 
Pleural effusion/ascitis 4 (4%) Bone involvement 1 (1%) 
Unknown 11 Unknown 8 
3 nodal areas,  with LN ≥ 3 
cm 
1 (1%) Kidney/liver 
involvement 
1 (1%) 
Unknown 
 
25 Unknown 11 
ECOG ≥2 
 
3 (3%) Cytopenia  1 (1%) 
Unknown 
 
 
 
29 Unknown 10 
LDH ≥ULN 3 (4%) B2M ≥ULN 5 (5%) 
Unknown 25 Unknown 81 
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Figure 14: TT according to FLIPI risk groups 
 
 
Figure 15: TT according to FLIPI2 risk groups 
 
There was a trend towards a shorter TT for patients with at least one GELF criteria versus 
those with none (median TT: 32 months versus 49 months, p=0.06). Likewise, patients that 
had at least one BNLI criteria had a trend towards a shorter median TT than the rest (19 
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months versus 43 months, p=0.09). The TT was significantly shorter in the 24 patients with at 
least one GELF or BNLI criteria than in patients with no treatment criteria at all (p=0.03) 
(figure 16). 
 
Figure 16: TT in patients with >1 GELF/BNLI treatment criteria in comparison with patients 
with no criteria for treatment 
 
 
 
 
 
 
 
 
 
 
 
4.3.5 Overall survival  
Thirty-eight patients have died, including 6 patients that had not required any treatment for 
FL. The causes of death were related to lymphoma in 19 patients, other malignancies in 3 
patients and other causes in 16 patients. The cause of death was unrelated to lymphoma in 
the 6 patients that died without having required treatment for FL.  The 5-year, 10-year and 
20-year OS of the patients managed expectantly were 77% (95%CI: 68-85%), 58% (95%CI: 46-
68%) and 34% (95%CI: 19-50%), respectively. The OS of the study group was not significantly 
different from that of the group of patients treated at diagnosis (p=0.83) (figure 17). 
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Figure 17: OS of patients managed expectantly versus those treated immediately after 
diagnosis 
 
 
 
Having one or more treatment criteria according to GELF or BNLI had no impact on OS (p=0.9 
and p=0.6, respectively). In contrast, the FLIPI and FLIPI2 predicted OS (p=0.001 for both) and 
both indices identified a high-risk population with a shorter OS. However, the OS of patients 
with high-risk FLIPI managed expectantly was not significantly different from the OS in 
patients with high-risk FLIPI treated at diagnosis (p=0.7) (figure 18). 
 
Figure 18: OS of patients with high-risk FLIPI according to whether they were managed 
expectantly or treated at diagnosis 
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 4.4 Discussion 
The FLIPI score is one of the factors (in addition to age, stage and the histological grade) that 
was found to influence the initiation of therapy by physicians in the National Lymphocare 
Study (54). In contrast, in our study the percentage of patients in each risk group according to 
the FLIPI and the FLIPI2 prognostic indices did not differ significantly between patients 
managed expectantly and those patients treated at diagnosis (p=0.89, p=0.22 for FLIPI and 
FLIPI2, respectively), suggesting that neither the FLIPI nor the FLIPI2 were taken into account 
to decide initiation of treatment. Of note, almost a quarter of the patients managed 
expectantly had a high-risk score according to the FLIPI. Both the FLIPI and the FLIPI2 indices 
identified patients managed expectantly with a high-risk score that have a shorter OS than 
patients with a low- or intermediate-risk score, and were more likely to receive treatment 
earlier. Thus, in our study patients with high-risk FLIPI were treated at a median of 2.6 years 
in comparison to a median of 5 years for low-risk patients.  The current results suggest that 
the FLIPI should not be used to guide treatment decisions at diagnosis in terms of the 
indication for treatment, as the OS of patients in the high-risk category did not differ 
between patients managed expectantly and those treated immediately. However, it might be 
used to identify a high-risk cohort of patients that may need to be followed up more closely 
as they are likely to need treatment earlier. The number of patients managed expectantly in 
whom the FLIPI2 score could be assigned in our series is too small to be able to draw similar 
conclusions for this index. 
Despite being managed expectantly, a number of patients in our series were found to have 
one or more treatment criteria according to the GELF or BNLI criteria. Although the TT was 
shorter in patients having GELF or BNLI criteria, this did not reach statistical significance, 
probably due to the small number of patients included. When combining the patients that 
had at least one GELF or one BNLI criteria, the difference in the median TT between those 
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patients with at least one criterion and those without criteria for treatment reached 
statistical significance. When analysing if there was an effect on OS, having a treatment 
criteria did not affect the OS of patients. It is important to convey this message to patients, as 
being ‘symptomatic’ might mean requiring treatment, but in itself may not imply a worse 
prognosis in the long term. 
 
4.5 Conclusions 
This long follow-up study confirms that around one third of the patients with asymptomatic 
FL do not require treatment for a prolonged time and adds further support to an expectant 
management approach in asymptomatic patients. Neither the FLIPI nor the FLIPI2 are able to 
identify a population in whom initial management results in a better prognosis. The FLIPI 
does identify a high-risk population more likely to be treated earlier than the remainder and 
with a shorter OS, but the OS of these patients does not differ significantly from that in 
patients treated immediately at diagnosis. 
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5.1 Introduction 
A major advancement in the treatment of patients with FL has been the development of the 
chimeric anti-CD20 MoAb rituximab. Rituximab has become an essential component of FL 
treatment, either in combination with chemotherapy or as maintenance (69, 74, 111). In 
recognition of the importance and prevalence of rituximab treatment, many authors now 
distinguish a pre-rituximab from a rituximab era in the management of patients with FL. In 
contrast, HDT/ASCR has been utilised in both newly diagnosed and relapsed FL patients to 
prolong remission duration since the late 1980 era (80, 82, 91). The high-dose regimen 
received as the conditioning regimen can be either chemotherapy-based or total-body 
irradiation (TBI)-based. There have been concerns about an increased NRM in TBI-treated 
patients due to a higher incidence of sMDS/AML in comparison with patients treated with 
chemotherapy-based conditioning regimens (89). This has lead to a shift to chemotherapy-
based conditioning regimens in most centres, including Barts. However, there has never been 
a randomised trial comparing the different conditioning regimens (chemotherapy-based 
versus TBI-based) in FL patients, that would add further evidence of the higher risk of 
sMDS/AML associated with TBI by controlling other factors. Of note, most available studies 
examining the role of HDT/ASCR in patients with FL have been performed in the pre-
rituximab era, so there is limited available data regarding the influence of prior rituximab on 
the survival of patients with FL after HDT/ASCR.  
Against this background, the aim of this Lymphoma Working Party (LWP)-EBMT study was to 
assess the outcome of patients with FL having HDT/ASCR according to the high-dose regimen 
received and according to whether they had received previous treatment with rituximab.  
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5.2 Patients and methods 
5.2.1 Patients  
Between 1995 and 2007, 7910 adult patients with FL had HDT/ASCR and were reported to 
the EBMT registry. Patients were included in the current study if they had received TBI or the 
chemotherapy-only regimen BEAM (BCNU, etoposide, cytarabine and melphalan) as 
conditioning regimens. Patients with histological transformation at the time of HDT/ASCR 
were excluded as well as those undergoing a second transplant. A complete data set was 
available for 2233 FL patients, which constitutes the study group.  
 
5.2.2 Response definitions 
Complete response (CR) was defined as the complete disappearance of disease and related 
symptoms. A very good partial response (VGPR) was defined as a reduction in tumour burden 
of at least 90%. Partial response (PR) was defined as a reduction in the burden of disease by 
at least 50% or more. According to EBMT definitions, relapse is the occurrence of new sites of 
disease, or the re-occurrence of disease or systemic symptoms after having achieved a CR 
which lasted for 3 months or more. Progressive disease (PD) is the occurrence or 
reoccurrence of new disease sites or symptoms if CR lasted less than 3 months. Progression 
also describes any worsening of the disease status in patients previously assessed as not in 
CR. Stable disease (SD) is defined as achieving less than a PR but not fulfilling criteria for 
progressive disease. Primary refractory disease is defined by a lack of response to treatment 
and progression of the disease. For the purpose of this analysis, primary refractory, SD, 
relapsed and progressive disease were grouped together as active disease. First complete 
response (CR1), first partial response (PR1) and first very good partial response (VGPR1) were 
grouped together as first remission (remission 1). Subsequent CR or PR were grouped 
together as subsequent remission (remission>1). 
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5.2.3 Outcome measures 
OS was measured from the time of HDT/ASCR to death from any cause. EFS was measured 
from the time of HDT/ASCR to progression, reoccurrence of the disease or death from any 
cause. NRM was defined as death from any cause without progression.  
 
5.2.4 Statistical analysis 
Patient characteristics were compared with a t-test for continuous variables and a chi-square 
or Fisher test for categorical variables. OS and EFS were determined using the Kaplan-Meier 
method, and curves were compared by the log-rank test. The relevance of prognostic factors 
was validated by multivariate analysis using the Cox model. Incidence of relapse (IR) and NRM 
were calculated by cumulative incidence curves to account for competing risks and compared 
by Gray test. The relevance of prognostic factors was validated by multivariate analysis 
utilising the Fine and Gray model. 
 
5.3 Results 
5.3.1 Patients’ characteristics 
Six hundred and eighty patients received a TBI-containing regimen and 1553 patients 
received BEAM. The main characteristics of the patients according to the regimen received 
are described in table 20. A total of 1098 patients (49%) were in first remission, 619 (28%) 
received HDT in remission>1 whereas 398 patients (18%) had active disease at the time of 
HDT. The response at the time of HDT/ASCR was unknown in 118 cases (5%). Seven hundred 
and thirteen patients (32%) had been treated with MoAb before HDT/ASCR (confirmed as 
rituximab in 665). Two thousand one hundred and seven patients (94%) received peripheral 
blood as the source of stem cells, whereas 66 patients (3%) received BM. The number of 
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patients receiving BEAM conditioning regimen and MoAb prior to HDT/ASCR progressively 
increased per study year, while the number of patients treated with TBI declined (figure 19).  
 
Table 20: Patients’ characteristics according to the conditioning regimen received 
 
 
Figure 19: Patterns of use of TBI, BEAM and MoAb during the study period 
Patients characteristics BEAM 
(n=1553) 
TBI 
(n=680) 
p-
value 
Age median (range) 49 years (18 -72) 47 years (21-66) < 0.01 
Gender (female) 46% 43% 0.2 
Time from diagnosis to HDT/ASCR (median) 30 months 18 months <0.001 
Time from diagnosis to HDT/ASCR <1 year 21% 39% <0.001 
Disease status   <0.01 
Remission 1 44% 60%  
Remission>1 32% 18%  
Active disease 17% 19%  
MoAb prior to HDT/ASCR 37% 21% <0.01 
Peripheral blood stem cells (PBSC) 98% 93% <0.01 
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5.3.2 Non-relapse mortality (NRM)  
The 5-year NRM for the whole group was 7% (95% CI: 6-8%, figure 20). On univariate analysis 
there were no significant differences between patients treated with TBI and patients treated 
with BEAM conditioning regimen (figure 21).  
 
Figure 20: NRM and IR for the whole group 
 
 
Figure 21: NRM according to the conditioning regimen  
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On multivariate analysis for NRM, increasing age, time from diagnosis to HDT/ASCR >1 year, 
male gender, no previous MoAb treatment, and BM as the source of stem cells were all 
predictors of an increased NRM (table 21). 
 
Table 21: Multivariate analysis for NRM 
 
 
5.3.3 Incidence of relapse (IR) 
After a median follow-up of 60 months, the IR was 39% (95% CI: 37-42%; figure 20). The 5-
year IR was significantly better in patients treated with TBI (33%, 95% CI: 29-37%) compared 
to patients treated with BEAM conditioning (42%, 95% CI: 39-45%; figure 22). 
 
Figure 22: IR according to the conditioning regimen 
Factors associated with increased NRM  HR (95% CI) p-value 
Age (for one year increase)                         1.0 (1.0-1.04) 0.04  
Time from diagnosis to HDT/ASCR (>1 year versus <1 year)  1.6 (1.04-2.5) 0.03  
Male versus female  1.4 (1.1-2)  0.02  
No MoAb versus previous MoAb  1.7 (1.2-2.5)  0.005  
BM versus PBSC  2.0 (1.2-3.6)  0.007  
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On multivariate analysis of IR, patients treated with BEAM conditioning were more likely to 
relapse than patients treated with TBI conditioning, as well as patients treated with active 
disease in comparison with those treated in first or subsequent remission (table 22). 
 
Table 22: Multivariate analysis for IR  
 
 
5.3.4 Event-free survival (EFS) 
The median EFS for the whole group was 72 months, with a 5-year EFS of 53% (95% CI: 51-
55%). On univariate analysis patients who had BEAM conditioning had significantly shorter 
EFS than patients who received TBI (5-year EFS: 50% versus 60% respectively) (figure 23). In 
addition, patients that had received previous MoAb treatment had a longer EFS than patients 
that did not (5-year EFS: 56% versus 52%) respectively (figure 24). 
 
Figure 23: EFS according to the conditioning regimen 
Factors associated with increased IR  HR ( 95% CI) p-value 
BEAM versus TBI 1.4 (1.2-1.7) <0.001  
Disease status at ASCT (specified category versus remission1) 
Active disease 
Remission>1 
Unknown  
 
1.5 (1.3-1.9)  
1.0 (0.8-1.3) 
1.0 (0.7-1.5) 
 
<0.001 
0.8 
0.8  
 
Chapter Five 
 80 
 
Figure 24: EFS according to previous MoAb treatment 
 
 
On multivariate analysis the following factors retained significance and predicted a shorter 
EFS: BEAM conditioning, increasing age, no previous MoAb treatment and BM as source of 
stem cells (table 23). 
 
Table 23: Multivariate analysis for EFS 
 
Factors associated with a shorter EFS HR (95% CI) p-value 
BEAM versus TBI  1.4 (1.2-1.7) <0.001  
Age (for 1 year increase)                          1.0 (1.0-1.01) 0.04  
No MoAb versus previous MoAb  1.2 (1.1-1.4) 0.009  
BM versus PBSC  1.3 (1.0-1.7) 0.04  
 
 
5.3.5 Overall survival (OS) 
 
A total of 536 deaths occurred in the whole group (167 in patients receiving TBI and 369 in 
the BEAM group). Two hundred and seventy-seven patients died due to relapse or 
progression of disease, 37 patients due to secondary malignancies, 128 patients due to 
HDT/ASCR related causes, 32 patients due to other causes unrelated to HDT/ASCR, whereas 
the cause of death was unknown or missing in 62 patients. The median OS for the study 
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population was 146 months. The 5-year OS was 75% (95% CI: 73-76%) for the whole group. 
On univariate analysis BEAM conditioning regimen was associated with a shorter OS than TBI 
conditioning regimen (5year OS: 74% versus 78% respectively) (figure 25). In addition, 
patients that had received previous MoAb treatment had a longer OS than patients that did 
had not received prior MoAb (5 year OS: 80% versus 74%, respectively) (figure 26). 
 
Figure 25: OS according to the conditioning regimen  
 
 
  Figure 26: OS according to previous MoAb treatment 
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On multivariate analysis (table 24), patients treated with BEAM conditioning tended to have a 
shorter OS than patients treated with a TBI-containing conditioning regimen (p=0.06). In 
addition, the following factors predicted a shorter OS: increasing age, no previous MoAb 
treatment, time from diagnosis to ASCT>1 year and BM as the source of stem cells. 
 
Table 24: Multivariate analysis for OS 
 
Factors associated with a shorter OS HR (95% CI) p-value 
BEAM versus TBI  1.2 (1.0-1.4) 0.06  
Disease status at BMB (specified category versus remission1) 
Active disease 
Remission>1 
Unknown 
 
1.4 (1.1-1.8)  
0.9 (0.7-1.2)  
1.2 (0.8-1.8)  
0.001  
Age (per 1 year increase) 1.02 (1.01-1.03) <0.001 
No MoAb versus previous MoAb 1.4 (1.1-1.7)  0.003  
Time from diagnosis to ASCT (>1 year versus <1 year) 1.3 (1.02-1.6)  0.03  
BM versus PBSC 1.7 (1.2-2.3) <0.001 
 
 
5.4 Discussion 
Several randomised trials have demonstrated an improved PFS and, importantly, an 
improved OS in patients diagnosed with FL treated with rituximab in combination with 
chemotherapy in comparison with those treated only with chemotherapy (67, 69-70). Hence, 
since its approval by the FDA in 1997, there has been a steady increase in the use of 
rituximab in the treatment of patients with FL prior to progressing to HDT/ASCR. This is 
corroborated in our study, which clearly shows a steady increase in the use of rituximab since 
1997. In contrast with DLBCL, the data on the effect of prior rituximab treatment on the 
outcome of patients diagnosed with FL undergoing an HDT/ASCR is still limited. In the CORAL 
study patients who had received prior rituximab treatment had a worse EFS following salvage 
chemotherapy and HDT/ASCR than patients that had not received prior rituximab treatment, 
suggesting that patients relapsing after rituximab treatment may have developed a more 
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resistant disease that is less likely to respond to salvage with HDT/ASCR. In the study by 
Ladetto et al comparing the outcome of patients treated with HDT and rituximab (R-HDT) 
followed by ASCR and that of patients treated with R-CHOP, there was no difference in the 
OS between both arms. In this study, patients that had relapsed after treatment with R-CHOP 
had a good salvage rate with R-HDT and a very good EFS of 68% at 3 years, suggesting that 
patients who relapse after a rituximab-containing regimen are still salvageable with HDT, 
contrasting with the situation in patients with DLBCL (112). Another study by Sebban et al 
reported that patients that had rituximab as part of the salvage treatment prior to HDT/ASCR 
had a better outcome in terms of 5-year EFS and survival after relapse (SAR) (67% and 93%, 
respectively) in comparison with a 5-year EFS and SAR of 46% and 63% for patients who did 
not receive rituximab as part of the salvage treatment (93). Our study is consistent with the 
positive outcome of patients treated with rituximab prior to HDT/ASCR in FL. In the current 
study patients that had received rituximab prior to HDT/ASCR had a significantly better 
outcome in terms of EFS and OS (at 5 years: 56% and 80%, respectively) than patients that 
were rituximab naïve at the time of HDT (5-year EFS and OS: 52% and 74%, respectively). This 
result is reassuring in FL patients, as it confirms that HDT/ASCRT remains an excellent salvage 
option in patients previously treated with immuno-chemotherapy. 
Another important question in the treatment of patients with FL is the type of conditioning 
regimen to be utilised in HDT/ASCR. TBI-based conditioning regimens were reasonably 
incorporated into HDT based on the known sensitivity of FL to radiation (113). The type of 
conditioning regimen had a significant impact on the IR in our study. Patients receiving a TBI 
regimen were less likely to relapse and had a better EFS on multivariate analysis in 
comparison to patients treated with the BEAM conditioning regimen. The reduced IR in our 
study is consistent with the results of a previous EBMT study in the pre-rituximab era that 
also concluded that patients receiving TBI condition were less likely to relapse than those 
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who received a non-TBI-based conditioning regimen (89). A previous study also suggested an 
improved failure-free survival following HDT/ASCT patients receiving a TBI-based 
conditioning regimen (96). However, the increased risk of development of sMDS/AML in 
patients treated with TBI conditioning was felt to outweigh the benefit of an improved IR in 
both of the above studies. In the study by Montoto et al, the increased NRM in the TBI 
treated group, contributed to a reduced OS in patients treated with TBI in comparison with 
those who did not receive TBI. In contrast, in our study both groups of patients had a similar 
NRM (7% at 5 years), which led to a lack of differences in the OS of both groups of patients 
on multivariate analysis. 
 A well known side-effect of HDT/ASCR is the development of sMDS/AML or other 
malignancies in the long-term [a risk between 5 and 20% has been reported for sMDS/AML 
and around 10% at 10 years for other second malignancies (100)]. Several studies have 
shown an association of TBI with an increase in the incidence of sMDS/AML after HDT/ASCR 
(82, 89, 96, 100)in comparison to chemotherapy-based regimens. Given the evidence of an 
increased risk of sMDS/AML after HDT/ASCR, there has been a considerable decrease in the 
use of TBI as part of the conditioning regimen. This is reflected in our study which shows a 
steady decline in the use of TBI conditioning in Europe since 1997. Several factors other than 
TBI have also been implicated in the risk of secondary malignancies, such as age, inclusion of 
etoposide in the conditioning regimen, cytogenetic abnormalities prior to transplant, 
previous radiotherapy exposure, prior alkylating therapy, number of prior lines of treatment 
and increased interval from diagnosis to HDT/ASCR (97, 99, 101, 114). One of the flaws of the 
present study, inherent to its retrospective/registry-based nature, is the difficulty to 
ascertain accurately the number of secondary malignancies that may have occurred in 
patients still alive in both groups. This additional information will require further follow-up of 
the participating centres. A recent Cochrane review including prospective studies comparing 
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HDT/ASCR (all had utilised TBI as part of the conditioning) and chemotherapy and immuno-
chemotherapy regimens in untreated FL patients found no significant difference in the 
occurrence of secondary malignancies between both arms. However, as the follow-up in all 
the studies included in the Cochrane review was shorter than 10 years this conclusion needs 
to be taken with caution (115).  
The OS of patients in this study (75% at 5 years) is encouraging, as it compares well with the 
previous EBMT study (albeit with a very different population) which reported an OS of 64% at 
5 years. This suggests a continued improvement in the survival of patients undergoing 
HDT/ASCR, which might partially be due to the inclusion in the current study of patients 
previously treated with rituximab, which seems to have a positive effect on outcome as 
reported by the GELA group. In addition, the improved supportive care given to patients has 
most likely impacted on the outcome of patients receiving HDT/ASCR in the rituximab era.  
 
5.5 Conclusions 
The outcome of FL patients after HDT/ASCR appears to be improving in the current rituximab 
era. This is possibly due to the introduction of more effective novel treatments and better 
supportive care offered to these patients. Patients treated with TBI conditioning are less 
likely to relapse and may have a better outcome than patients treated with chemotherapy-
based conditioning regimens. However, these results will need to be confirmed on a longer 
follow-up, before final conclusions can be drawn. 
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The clinical course of patients diagnosed with 
follicular lymphoma in the rituximab era 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Six 
 87 
6.1 Introduction 
Several studies published in the last decade have reported for the first time an improvement 
in the OS of patients diagnosed with FL in more recent years. This improvement has been 
attributed to several factors including treatment with rituximab, HDT/ASCR and improved 
supportive care of patients (12, 14). However, despite these significant improvements, FL 
remains an incurable disease. Given the lack of a curative treatment there is no consensus on 
the best treatment to be utilised at diagnosis or relapse. However, there is generalised 
agreement that the treatment offered should contain rituximab, due to the better outcomes 
achieved with rituximab-containing regimens (69-70, 75), which has led to the term 
‘rituximab era’ to be coined. 
Johnson et al described in 1995 the pattern of relapse in patients with FL in the pre-rituximab 
era (10). Since then, a decrease in the rate of response, in addition to a gradual decrease in 
the length of response duration, an increase in the relapse rates and a shortened survival 
with each subsequent relapse has been considered the characteristic clinical course in 
patients with FL. However, the treatment of FL has undergone major changes since this 
pivotal study was published with the introduction of MoAb treatment. In addition, HDT/ASCR 
has a more widespread use as salvage treatment and the advent of RIC regimens has 
broadened the population of patients eligible for an allogeneic transplant. A further study 
examining the pattern of survival of FL patients in the current rituximab era has not been 
reported.  
Against this background we hypothesised that these therapeutic options have resulted in a 
change in the clinical course of patients with FL, so that the response rates, response 
durations and relapse rates do not decrease with each subsequent relapse. To test this 
hypothesis we analysed the duration of remission, response rates, and relapse rates in 
addition to the OS and PFS of patients diagnosed with FL in the rituximab era. 
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6.2 Patients and methods 
6.2.1 Patients’ characteristics 
For the purpose of this study, we arbitrarily defined the rituximab era as starting in 1997, as 
this is when an anti-CD20 MoAb was first used in our institution to treat patients with FL (in 
the setting of a clinical trial). Hence, between 1997 and 2007, 177 patients (median age: 56 
years, range 25-89) were diagnosed with grade 1-3a FL and constitute the study population. 
Ninety-six patients received rituximab at some point as part of their treatment (77 patients 
received rituximab as part of one treatment line, 16 patients as part of 2 separate treatments 
and 3 patients as part of 3 different treatments), while 81 patients have never received 
rituximab. Patients’ characteristics at diagnosis are shown in table 25. Amongst patients who 
received rituximab 34/96 (35%) had histological transformation during the course of their 
disease (and 29 patients had received rituximab treatment at the event of transformation), 
contrasting with 15 of 81 rituximab-naïve patients (18%) (p=0.016). In addition, a higher 
proportion of patients who received rituximab during the course of the disease had been 
diagnosed with advanced stage (stage III-IV: 78% in contrast with 56% in rituximab naïve 
patients, p<0.001).  
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Table 25: Patients' characteristics  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.2.2 Definitions of response 
Response was categorised according to the standard international criteria published in 1999 
(116).  Response rate (RR) included CR/CRu and PR. Best response was defined as the first 
optimum response (CR, CRu or PR) a patient had achieved irrespective of the number of 
treatments required to achieve that response.  
 
 
 
 
 
 Rituximab naïve 
(n=81) 
Treated with 
rituximab (n=96) 
p-value 
Age, median (range)  57 years (28–89) 55 years (25-87) 0.85 
Gender (female) 34 (42%) 52 (54%) 0.16 
Stage <0.001 
I 23 (29%) 4 (4%)  
II 12 (15%) 17 (18%)  
III 13 (16%) 20 (21%) 
 
 
IV 32 (40%) 55 (57%)  
unknown 1 0  
Grade 0.86 
1 38 (48%) 41 (45%)  
2 26 (33%) 29 (31%)  
3a 15 (19%) 22 (24%)  
Unknown   2 4  
FLIPI 0.54 
1 29 (50%) 27 (41%)  
2 15 (26%) 18 (27%)  
3 14 (24%) 21 (32%)  
unknown 23 30  
Initial management 0.54 
Expectant 40 (49%) 43 (45%)  
Treated 41 (51%) 53 (55%)  
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6.2.3 Definitions of study end-points 
OS was measured from the date of diagnosis to the date of last follow-up or death. Duration 
of best response was measured from the best response achieved to relapse (in patients 
achieving CR/CRu) or progression (in patients achieving PR). 
 
6.2.4 Statistical analysis  
Survival analysis and duration of remission was performed by the Kaplan-Meier method and 
Cox-regression test was used to test for significant associations where appropriate. For 
continuous data t-test was utilised and for categorical data the chi-square test was used. All 
statistical analysis was carried out on STATA. 
 
6.3 Results 
6.3.1 Patients’ follow-up and management 
The median follow-up was 7.3 years (range: 1.2-14). There were no significant differences in 
the median follow-up of patients treated with rituximab (7.2 years) and that of rituximab-
naïve patients (7.8 years). One hundred and fifty patients received treatment at some point 
during the follow-up, while 27 patients never received any treatment, and were managed 
expectantly (median follow-up: 6.5 years, range: 1.2-13.1). In the rituximab-treated group 42 
patients received rituximab as part of the first treatment (R-CHOP: 24 patients; R-
chlorambucil: 13 patients and single agent rituximab, 5 patients), while 43 patients received 
rituximab as part of the second line treatment and 33 at third or subsequent treatments. In 
the rituximab-naïve group, 16 patients received CHOP, 13 patients received localised RT, 20 
patients received monotherapy with chlorambucil or cyclophosphamide, 4 patients received 
a fludarabine-based regimen, and one patient was treated for lymphoblastic transformation 
with the UKALL12 protocol. Six patients had HDT/ASCR in the first event, 15 in the 2nd event 
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and only 1 patient had HDT/ASCR in the 3rd event. Two patients had an allograft (in the 2nd 
and 3rd event).  
 
6.3.2 Overall survival and progression-free survival 
The OS of patients with FL diagnosed and treated at St Bartholomew’s Hospital has 
significantly improved between 1977 and 2007: the median OS for patients diagnosed in the 
rituximab era (1997-2007) is 13 years, compared to 11 years for 124 patients diagnosed 
between 1985 and 1996 and 7 years for patients diagnosed from 1977 to 1984 (n=105) 
(figure 27). 
 
Figure 27: OS of patients diagnosed with FL from 1977 to 2007 at St Bartholomew’s Hospital 
 
 
The 5-year and 10-year OS for the 177 patients diagnosed in the rituximab era was 78% 
(95%CI: 71 – 83%) and 61% (95%CI: 52-69%) respectively, while the PFS for the whole group 
was 38% (95%CI: 31- 46%) and 23% (95%CI: 16-32%) at 5 and 10 years, respectively (figure 
28). The survival of the 27 patients who never needed any treatment was significantly 
superior to that of the remainder (p=0.03). Amongst the 150 patients that received 
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treatment for FL during follow-up, there was a trend for a better OS for patients in the 
rituximab-treated group than for rituximab-naïve patients: 5-year and 10-year OS for the 
rituximab-treated group were 80% and 62% respectively, while in the rituximab-naïve group 
the 5-year and 10-year OS were 60% and 47%, respectively (p=0.06) (figure 29). 
 
Figure 28: OS and PFS of the study population 
 
 
 
Figure 29: OS of treated patients according to whether they received rituximab or not 
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6.3.3 Response rates and duration of remissions 
The RR decreased by only 10% with each relapse, whereas the duration of the remissions did 
not decrease with subsequent treatments. The median duration of first response (from best 
response) was 2.8 years whilst the median second response duration was 3.5 years and the 
median duration of the 3rd remission has not been reached (figure 30, table 26). A similar 
pattern was observed when analysing only the rituximab-treated group (n=96). In this 
subgroup the median duration of the first remission was 2.4 years, while the median duration 
of second response was 4.5 years, and the median duration of the third remission was not 
reached.  
 
Figure 30: Duration of remissions from best responses for the study group 
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Table 26: Response rate, duration of remission, relapse rate and survival for each event 
 
 
 
6.3.4 Timing of treatment with rituximab 
The outcome of patients who received rituximab was also analysed. Amongst them, 42 
received rituximab as part of the first-line therapy, while 54 patients had received rituximab 
treatment as part of subsequent treatments. The median follow-up for the 42 patients who 
had rituximab as part of their initial treatment was 5 years, while it was 9 years for the 
remaining 54 patients. The median duration of response from first treatment for patients 
who had rituximab as part of their initial therapy was not reached whereas it was 1.5 years 
for patients that received rituximab not as part of the first treatment but subsequently 
(p<0.001) (figure 31).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Number 
of 
patients 
treated 
Patients 
treated 
with 
rituximab  
Response  
rate  
Median 
duration of 
best 
response  
Relapse 
rate  
Median 
survival 
from best 
response 
At 
presentation 
150 52 (34%) 91% 
(136/150) 
2.8 years 57% 
(78/136) 
12 years 
1st relapse 61  46 (75%) 83% 
(51/61) 
3.5 years 47% 
(24/51) 
10 years 
2nd relapse 16 11 (68%) 75% 
(12/16) 
Not 
reached 
33%  
(4/12) 
Not 
reached 
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Figure 31: Duration of first remission according to the timing of treatment with rituximab 
 
 
 
The duration of responses from the last treatment administered in the 42 patients that 
received rituximab as part of the first treatment is shown in figure 32, whereas the duration 
of responses for patients who had rituximab at a subsequent event is shown in figure 33. 
There were no significant differences in OS between patients that received rituximab as part 
of the first treatment and those who receive it as part of the second or subsequent 
treatments (figure 34). 
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Figure 32: Duration of remissions from last treatment in patients that received MoAb as part 
of their 1st treatment 
 
 
 MoAb treatment 
 Treatment not containing MoAb 
RIP: Dead 
Rx: on current treatment
           
 
Chapter Six 
 97 
Figure 33: Duration of remissions from last treatment in patients that had not received MoAb 
as part of the 1st treatment but at subsequent treatments 
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Figure 34: OS according to the timing of treatment with rituximab 
 
 
6.4 Discussion 
Horning et al published a seminal paper in 1993 demonstrating that between 1970 and 1993 
there had not been a significant improvement in the OS of patients diagnosed  with FL 
according to the year of diagnosis at Stanford University, despite the better response rates 
achieved by combination chemotherapy (11). The first study to demonstrate an improved OS 
in FL patients was reported by Swenson et al in 2005, showing that the outcome of patients 
diagnosed in more recent years (1990-1999) was significantly better with an improved OS in 
comparison with that of patients diagnosed in previous years. Furthermore, two subsequent 
studies from M.D. Anderson Cancer Center and SWOG confirmed these results, and partly 
attributed the improved OS to the use of MoAb in the treatment of patients diagnosed in the 
late 90’s, in contrast to only-chemotherapy treatment utilised in the previous decades (13-
14). In line with the results reported by the above studies, the current one demonstrates that 
there has also been a significant improvement in the survival of patients with FL diagnosed at 
Barts in the 1990s, with a median OS improving from 7 to 13 years. In our study a progressive 
decline was seen in the response rates of patients with each subsequent treatment. This is 
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similar to the results previously reported by Johnson et al analysing the clinical course of 
patients diagnosed with FL in our centre in the pre-rituximab era (10). In contrast, for those 
patients that did achieve a response, a progressive shortening of the duration of subsequent 
responses was not detected in the current study. On the contrary, the second response 
duration was longer than the first, and the median was not reached in patients achieving a 
third remission. This improved response duration is reflected in the relapse rate which also 
declined with each successive response. On sub-analysis of the rituximab-treated group 
(n=96) a similar pattern of improving response duration and relapse rate was also seen with 
each subsequent event of treatment. 
This improvement in the response duration can be attributed to both the introduction of 
rituximab and of HDT/ASCR. HDT/ASCR was introduced to practice in 1987 at St. 
Bartholomew’s hospital as consolidation of the response following a salvage regimen at first 
relapse and in patients that had required more than one line of treatment to achieve a first 
response. Monoclonal antibodies against CD20 were first used to treat patients diagnosed 
with FL at Barts in 1997 as part of clinical trials. Subsequently rituximab treatment became 
more accessible in 2005 when NICE approved rituximab for relapsed/refractory patients and 
in 2006 when it was approved as first-line treatment. As a result, in the present study a larger 
proportion of patients received rituximab treatment in the second event compared to the 
first event: 75% versus 34%. In addition, a larger number of patients underwent HDT/ASCR in 
second event than at first event. It is thus likely that the use at relapse of these very effective 
treatments has contributed to the prolonged response durations achieved in the second 
event. When analysing only the rituximab-treated group of patients, the response duration of 
patients that had received rituximab as part of their initial therapy was significantly longer 
than that of patients that received rituximab as part of subsequent treatments. However, the 
OS of both groups was similar, indicating that receiving rituximab as part of subsequent 
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treatments might have a similar effect in terms of survival than receiving it as part of the first 
treatment. This is consistent with the results reported by the prospective randomised trial 
EORTC 20981, which investigated the effect of maintenance with rituximab on PFS and OS in 
patients treated with second line R-CHOP or CHOP. After a median follow-up of six years 
there were no significant differences in the OS of patients that had received maintenance 
compared to those patients that did not. This was attributed by the authors to the high 
successful salvage rate with rituximab-chemotherapy at relapse in patients who had not 
received maintenance (117). Unfortunately, in our study the number of patients that 
received rituximab both as part of the first and subsequent treatment is very small. In 
addition, the follow-up of patients included in the PRIMA trial is still too short to have any 
indication on the effect of further treatments on response duration in patients relapsing after 
immuno-chemotherapy and maintenance rituximab (76). As immuno-chemotherapy followed 
by maintenance rituximab has become the current standard for first-line therapy, the 
proportion of rituximab-naïve patients will progressively decline and consequently, 
subsequent remission durations may eventually become similar in duration to the first one, 
rather than being longer. Nonetheless, for the time being there is still a significant group of 
patients who have not received rituximab as part of the initial therapy or did not receive 
maintenance with rituximab after first remission, especially in the United Kingdom where 
maintenance with rituximab following first-line treatment was not approved until 2011. 
 
6.5 Conclusions 
The clinical course of patients with FL has changed considerably in the rituximab era. The 
typical pattern of sequentially declining response durations and an increased likelihood of 
relapse following each treatment is no longer the course that one should expect in patients 
with FL. This change in response duration certainly needs to be taken into account when 
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planning and interpreting the results of future clinical trials in FL, in addition to when 
planning the clinical care of patients with FL. 
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FL is a heterogeneous incurable malignancy. The presentation and behaviour of the disease 
varies amongst patients: a proportion of them will never require treatment, and remain 
asymptomatic, while some patients’ disease will progress rapidly and may transform to a 
more aggressive form of lymphoma. As a result, the management options are also diverse 
ranging from expectant management to an allogeneic transplant, with the same patient 
being a candidate for these opposed modalities of treatment at some point. A typical patient 
will receive several courses of treatment during the course of their disease. The lack of 
improvement in the OS of patients diagnosed with FL over decades, despite the improved 
response rates achieved by more intensive chemotherapy regimens (11) became one of the 
paradigms of this disease. However, recently an improvement in the OS of patients 
diagnosed with FL in more recent years has been demonstrated, as a result of better 
supportive care and the introduction of newer treatment options (12-14). In addition to 
newer treatment options, better staging and prognostication tools are essential to contribute 
to improve the outcome of any malignancy. In this regard, a new imaging modality, FDG-
PET/CT, has proven of great value in the staging and assessment of response to treatment in 
patients with lymphoma. Furthermore, a new prognostic index designed specifically for FL, 
the FLIPI2, has been developed in this current era. This thesis has examined how the 
introduction of such advances has impacted on the management and on the clinical course of 
patients with FL.  
Given the prolonged OS patients with FL are expected to achieve in the current era, PFS is 
deemed a reasonable end-point of studies, as it is considered more achievable and realistic. 
In line with this, a new clinical prognostic index, the FLIPI2, was designed in the rituximab era 
with PFS as the primary end-point (48). The efficacy of the FLIPI and FLIPI2 indices in 
predicting both OS and PFS in our population of FL patients diagnosed at Barts were 
compared. The FLIPI2 clearly groups together a large segment of the population into the 
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intermediate-risk group: in our study 66% of patients belonged to the intermediate-risk 
category. This is a consequence of the reduction in the number of required risk factors in the 
low-risk category: from 0-1 in the FLIPI to none in the FLIPI2 (48). As around 80% of FL 
patients present with advanced stage, and more than half have BM involvement, over 50% of 
the patients are included in the intermediate or high-risk category according to the FLIPI2. 
This unequal distribution is clear in the original description of the FLIPI2 by Federico et al 
where 57% of the patients were assigned an intermediate-risk score (48). As a result of the 
unbalanced distribution, a smaller number of patients are allocated to the high and low-risk 
categories. This defeats the purpose of a prognostic score in identifying distinct risk groups of 
patients that might warrant different management, and contrasts with the balanced 
distribution according to the FLIPI, both in the original description (low, intermediate and 
high-risk: 36%, 37% and 27%, respectively) and in our series (42%, 29%, 28%). In our study, 
the FLIPI2 could identify a high-risk population but failed to differentiate the low-risk and the 
intermediate-risk groups according to OS, which might be related to the fact that the FLIPI2 
was not designed with OS as the main end-point. In addition, both prognostic scores failed to 
differentiate the low-risk and the intermediate-risk groups according to PFS, possibly due to 
the different treatment regimens these patients had received. Indeed, PFS is a reflection not 
only of the ‘aggressiveness’ of the underlying disease, but also of the efficacy of the 
treatment administered. Patients included in the study by Federico et al had a 
heterogeneous treatment, with 60% of the patients receiving rituximab treatment. It might 
not be possible to reproduce the results of the FLIPI2 with PFS as the end-point in a different 
group of patients treated with different chemotherapy regimens. In contrast, OS as an end-
point is a reflection of all the treatment lines a patient has had and is less subject to bias than 
PFS (109, 118). As the definition and the documentation of the time of progression is liable to 
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bias, and may differ between studies if PFS is to be used as an end-point, patients to be 
compared should have received a similar treatment.  
Prognostic factors should be useful to predict the outcome of patients, in addition to possibly 
guide treatment (119), especially in a disease as FL where the choices at diagnosis include 
expectant management. However, in FL the FLIPI is not used to guide treatment, but it has 
been utilised to define study populations in clinical trials (120). In our study we demonstrated 
that the proportion of patients in each risk group according to either the FLIPI or FLIPI2 were 
similar in patients that have been treated at diagnosis and patients that have been managed 
expectantly. In addition, there was no difference in the OS of high-risk FLIPI patients 
managed expectantly in comparison with that of high-risk FLIPI patients treated at diagnosis. 
As in other institutions in the United Kingdom, the FLIPI score is not used at Barts to decide 
initiation of treatment of patients with FL. These results enforce this view. However, if the 
prognostic indices are not useful for guiding treatment, what other tools are available to 
make such decisions? Traditionally two sets of treatment criteria have been used to identify 
patients at diagnosis in whom expectant management is not advisable: the GELF and the 
BNLI criteria. These were selected from the experience of patients being treated on clinical 
trials (9, 64), but have never been validated in a prospective manner and they differ slightly 
between different clinical trials. One hundred and five patients were managed expectantly at 
diagnosis in our study. Surprisingly, 24 patients had at least one GELF or BNLI criteria for 
treatment, and were still managed expectantly. Although in our study the patients that had 
at least one criterion were treated earlier than patients that had none, the OS did not differ 
between both groups. It is undeniable, that, given, the retrospective nature of this study, 
there are significant missing data. Nevertheless, this study demonstrates that although the 
presence of symptomatic disease would lead to earlier treatment, it does not necessarily 
affect the OS of patients in the long term. Therefore, although both the FLIPI and the FLIPI2 
 Chapter Seven 
 106 
can segregate a high-risk population in terms of survival and time-to-treatment, a high-risk 
FLIPI should not be utilised as an indication to start treatment. On the other hand, although 
the presence of treatment criteria appears to influence the time-to-treatment, the presence 
of symptoms does not appear to affect the survival of patients diagnosed with FL, 
emphasising the differences between reasons to initiate therapy and predictors of outcome. 
The introduction of CT in the early  1980 era caused a revolution in the staging of lymphoma 
and led to several investigations such as lymphangiography and laparotomy becoming 
obsolete. In addition, it also led to the first modification of the Ann Arbor classification for 
staging of lymphoma in 1989 (18). PET technology has been available since the 1950’s, 
however it was the successful introduction of FDG as a PET tracer and subsequently the 
development of PET/CT technology which has put this technique in the forefront of research 
in lymphoma (25). Its unique ability to combine both anatomical and metabolic data has 
proven advantageous in detecting disease not apparent on CT imaging in lymphoma (27). In 
our institution the effective dose of radiation resulting from the low-dose CT component of 
FDG-PET/CT is 4.5 mSv, and for the FDG-PET is 8 mSv (121), with a total of 12.5 mSv 
compared to an effective dose of radiation of 15 mSv for an staging  CeCT. FDG-PET has been 
reported to identify up to a 51% increase in nodal disease and 89% increase in extra-nodal 
disease compared to standard imaging in FL patients (47). However, an increase in the 
identification of disease does not always lead to a change in the stage. A number of studies 
have shown that 11-40% of patients diagnosed with FL staged by FDG-PET/CT had a more 
advanced stage in comparison to standard staging methods (35, 44, 46). The wide range is 
likely to be due to different study populations, with FDG-PET results less likely to impact on 
the management in those populations with more advanced disease. Nevertheless, a change 
in stage does not always translate into a change in the management in FL, either, as other 
factors, such as the location of the disease and the presence of symptoms will also affect the 
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management decision. In our study, FDG-PET/CT identified more LN regions than CeCT as 
well as identifying two patients with bone involvement not apparent on CeCT. This resulted 
in a change of stage from limited to advanced stage and a potential change in the 
management in these patients. The effect of detecting additional involved LN regions by FDG-
PET/CT on the FLIPI score has not been previously described. In our study the detection of 
additional LN regions led to a change in the FLIPI score in 20% of patients and, as a result, 
more than 50% of patients were included in the high-risk category. Whether the patients 
identified by FDG-PET/CT staging as having a high-risk FLIPI have the same poor prognosis as 
patients recognised as high-risk by CeCT is unknown. To answer this question would require 
larger number of patients with a longer follow-up. However, it is important to acknowledge 
the effect that staging by FDG-PET/CT has on the FLIPI score, especially when it is used to 
compare different study populations. A meta-analysis published in 2004 examined the role of 
FDG-PET/CT in the assessment of BM involvement in both HL and NHL and showed that FDG-
PET/CT had a high specificity for the detection of a negative BM but the sensitivity, especially 
for NHL, was disappointing (43%). As a result the authors concluded that FDG-PET/CT could 
complement the BMB, but cannot replace it in the management of lymphoma (122). Most 
clinical studies agree that there is a significant rate of false negative FDG-PET/CT in patients 
with a positive BMB in ‘low-grade’ NHL and a few studies including FL patients reported a low 
sensitivity of 39% (34). The inadequacy of visual assessment of BM involvement is reflected in 
our experience, as in our patients the visual analysis of BM involvement had a high specificity 
but a sensitivity of only 31%. This is most likely related to the focal involvement of the BM in 
FL, making it difficult to be visualized on FDG-PET/CT, especially in patients with < 10% 
infiltration on the BMB, in contrast to the diffuse infiltration in aggressive lymphoma (33). 
We investigated the additional value of semi-quantitative measurements in the detection of 
BM involvement. Although absolute SUV measurements (SUVmax and SUVav) increase the 
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sensitivity of FDG-PET/CT for the detection of BM involvement, the best accuracy was 
reached by the use of ratios. Ratios minimise the error associated with absolute SUV 
measurements, as this decreases the bias encountered in SUV measurement by variations in 
blood sugar, uptake period and FDG injected activity that may affect an absolute 
measurement. Utilising SUVav/MBP ≥1 increased the sensitivity of FDG-PET/CT for detection 
of BM involvement to 88%, while maintaining a high specificity of 80%. Increasing the 
sensitivity of FDG-PET/CT in the detection of BM involvement may spare patients less likely 
to have BM involvement having a BMB. Nevertheless, it is still essential to perform a BMB in 
patients likely to have BM involvement to ascertain the histology of the disease, in particular 
to rule out the presence of ‘high-grade’ lymphoma. Our results demonstrate that staging by 
FDG-PET/CT leads to a change in the stage and in the management of a proportion of 
patients with FL. The use of SUV to increase the accuracy of FDG-PET/CT is feasible and the 
radiation exposure is not increased by FDG-PET/CT. Therefore, FDG-PET/CT should be the 
next logical step in the progress of imaging in FL. In line with this, if the results reported by 
Trotman et al  on the strong predictive value of the response assessed by FDG-PET/CT in 
patients receiving first-line immuno-chemotherapy for FL are confirmed in further studies, 
this will make a baseline FDG-PET/CT mandatory (123).  
A recent meta-analysis and a Cochrane review of HDT/ASCR treatment in FL have concluded 
that there is no evidence to support a role for HDT/ASCR in first remission in FL. In contrast, 
an improved PFS and possible OS benefit for patients in second or subsequent remissions 
undergoing HDT/ASCR has made of this an attractive treatment option in this setting (85, 
115). However, some questions, such as the optimal conditioning regimen remain open. In 
addition, as immuno-chemotherapy has become the standard treatment for FL patients, 
more patients will have been exposed to MoAb treatment before being offered HDT/ASCR as 
a treatment option. There is a paucity of studies examining the effect of previous rituximab 
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treatment on the outcome of patients with FL undergoing HDT/ASCR. Given the concerns on 
the potential adverse effect of prior rituximab in the outcome after HDT/ASCR –as had been 
described for patients with DLBCL (112)- the LWP-EBMT designed a retrospective study to 
analyse the impact of prior rituximab in patients having HDT/ASCR for FL. An additional 
objective was to study the effect of TBI-containing conditioning regimens in the prognosis of 
patients with FL. In our study we found a significantly improved EFS and OS in patients that 
had been previously treated with rituximab in comparison to patients that were rituximab 
naïve. This result is reassuring in FL patients, as it confirms the effectiveness of HDT/ASCRT 
even in patients previously treated with immuno-chemotherapy. Along the same lines, a 
retrospective analysis by the GELA demonstrated that patients previously treated with 
rituximab and undergoing HDT/ASCR had the best outcome in comparison with patients 
treated only with rituximab or with HDT/ASCR at second line (93). Nevertheless, further 
studies will need to evaluate the outcome of patients relapsing after having received 
maintenance rituximab. As patients treated on the PRIMA trial relapse (76), more data will 
emerge with regards to the effect of long-term MoAb exposure on the response to salvage 
treatments including HDT/ASCR. In our study in the rituximab era, patients treated with TBI 
conditioning regimen were less likely to relapse, and had an improved EFS on multivariate 
analysis, in comparison with those who received BEAM conditioning regimen, although there 
were no differences in OS. This is in contrast to a previous EBMT study in the pre-rituximab 
era that attributed the reduced OS in patients treated with TBI compared to chemotherapy 
regimens to an increased NRM, which was related to a significantly higher risk of sMDS/AML 
in patients treated with TBI (89). In our study, after a median follow-up of 5 years, patients 
treated with TBI or BEAM had a similar NRM, leading to a lack of differences in the OS 
between both groups of patients on multivariate analysis. The analysis of the incidence of 
secondary malignancies was not an end-point of our study, which would require a different 
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design, and therefore complete data is not available to be able to draw any meaningful 
conclusions on this aspect. A further study specifically addressing the risk of secondary 
malignancies according to different conditioning regimens should be carried out in the 
rituximab era. A study by Tarella et al reported an increased risk of solid tumours in patients 
who received rituximab as part of HDT/ASCR; despite this, patients treated with rituximab 
still had a better outcome in terms of OS than patients who did not receive R-HDT/ASCR. 
Furthermore, in this study patients treated with TBI were not found to have an increased risk 
of sMDS/AML, although only a very small proportion of patients had received TBI (124). In 
summary, our study demonstrates that HDT/ASCR remains an excellent treatment option for 
patients with relapsed FL in the rituximab era. For the time being, there is some suggestion 
from our study, that TBI results in a better outcome than BEAM. However, the current follow 
up is not long enough to draw a more decisive conclusion, so this remains an open question. 
   
There is no doubt that MoAb, particularly rituximab, has had a crucial impact on the 
treatment and outcome of patients with FL. Several prospective trials have demonstrated 
significant improved response rates, PFS and OS in patients treated with rituximab (69-70, 75, 
125-127). This has resulted in the current consensus that treatment for FL should include 
rituximab. In fact, in recognition of the importance and prevalence of rituximab treatment, 
many authors now distinguish a pre–rituximab from a rituximab era in the management of 
patients with FL. On the other hand, better supportive care and better salvage options 
including HDT/ASCR have contributed to an improved OS of patients diagnosed with FL in 
comparison to previous eras. This has changed the previous paradigm stating that no 
improvement in OS in patients with FL could be observed over a prolonged time, in spite of 
better responses. Our results confirm such paradigm shift, as patients diagnosed at Barts 
between 1997 and 2007 had a median OS of 13 years in comparison to a median of 11 years 
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and 7 years for patients diagnosed in 1985-1996 and 1977-1984, respectively.  Another 
accepted paradigm in FL is that all patients will eventually relapse following treatment, with a 
sequential reduction in the response duration and a shorter survival with each subsequent 
treatment. This notion is based primarily on a publication by Johnson et al in 1995 including 
patients treated at Barts between 1968 and 1987. Patients treated in that era had a response 
duration that decreased to 13 months after the second episode of treatment in comparison 
to 30 months at presentation. The median OS from best response also decreased from 9.6 
years at presentation to 4.9 years after the second episode of treatment (10). In our study 
examining the relapse pattern of FL patients in the rituximab era, we found considerably 
different results. Although the response rates were reduced with sequential relapses, the 
response duration following the second episode of treatment did not decrease in comparison 
to the response duration after the first episode of treatment. The median OS also did not 
seem to decline in the same proportion it did in Johnson et al study: the OS at presentation of 
FL in the rituximab era was 12 years, whereas it was still significantly long at 10 years after 
first relapse. The changes in the relapse pattern of patients are due to the improved 
treatment options at relapse currently available, in contrast to the situation 20 years ago. 
Patients in our study were more likely to have received MoAb treatment and/or had 
HDT/ASCR in the second episode of treatment. The successful salvage of relapsing patients by 
these treatment options has compensated for any possible acquired resistance they may 
have developed following the first treatment. In this sense, Davis et al explored the effect of 
re-treatment with rituximab in FL patients and reported that the second response duration 
patients experienced did not differ from the first, and in some cases it was even longer (128). 
In our study 45 patients received MoAb as part of their first treatment and, after a median 
follow-up of 5 years, only 11 patients had required re-treatment, of which 7 patients had 
been re-treated with a MoAb. Further data on the remission duration of patients re-treated 
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with rituximab is lacking and is a limitation of our study. It should be noted that not many 
patients included in our study had received maintenance with rituximab. Following the 
PRIMA trial reporting an improved PFS in patient receiving maintenance rituximab after first-
line treatment with immuno-chemotherapy, this has become the standard recommended 
treatment for advanced stage FL patients requiring treatment (43). As more patients receive 
rituximab as the initial therapy, the sequential response durations may either become similar 
to the first one or start to decrease as resistance to treatment develops, rather than being 
longer than the first response, as in the current study.  We found no differences in the OS 
between patients that had received MoAb as part of their first treatment and patients that 
had received MoAb in subsequent treatments. This is probably due to the successful salvage 
of rituximab-naïve patients with MoAb and HDT/ASCR. A similar effect was demonstrated in 
the EORTC trial that detected no OS advantage between patients that received maintenance 
rituximab at relapse and those patients who did not receive maintenance but received 
rituximab as part of the salvage therapy of the subsequent recurrence. Thus, the timing of 
MoAb treatment does not seem to make a difference in the OS of patients. In conclusion, 
MoAb has not only had a huge impact on the prognosis of patients with FL but it has also 
significantly altered the clinical course and the pattern of recurrences in these patients.  
 
To sum up, whereas the new FLIPI2 score needs to demonstrate that it can add a significant 
advantage in the management of patients with FL, there is growing evidence that FDG-
PET/CT imaging contributes to better disease detection at the time of staging, with a 
subsequent effect on the FLIPI score which should be recognised. Furthermore, the added 
value of quantitative measurements such as SUV should be further explored as they increase 
the sensitivity of FDG-PET/CT. With regards to the treatment of patients with FL, the advent 
of MoAb and the use of HDT/ASCR have changed the landscape to the point that previously 
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held beliefs in the management of patients with FL are no longer acceptable and should be 
re-evaluated in the current rituximab era.  
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